Top

Steven I. Sherman, M.D.

Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine

Present Title & Affiliation

Primary Appointment

Naguib Samaan Distinguished Professor in Endocrinology, Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Professor, Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX

Chair, Department of Endocrine Neoplasia and HD, The University of Texas MD Anderson Cancer Center, Houston, Texas

Research Interests

1. Novel therapies for advanced or metastatic thyroid carcinoma

2. Optimal primary treatments for thyroid carcinoma

3. New approaches to monitoring patients with thyroid carcinoma

Clinical Interests

The Endocrine Multidisciplinary Center brings together experts who treat cancers and related diseases of the thyroid, parathyroid, pituitary and adrenal glands. We also provide specialized care of genetic cancer syndromes, such as multiple endocrine neoplasia (MEN). For general clinic information, please visit the Endocrine Center's website listed here: Endocrine Center

For physician to physician referrals, please call our main office line at (713) 792-2841.

For new adult patient self referrals, please call our new patient referral coordinators at (713) 563-4400 or visit us at https://my.mdanderson.org/

International patients may complete this form International Center or contact the International Center at 001-713-745-0450.

For general department information, please select the link below.

Department of Endocrine Neoplasia and Hormonal Disorders

Education & Training

Degree-Granting Education

1985	Johns Hopkins School of Medicine, Baltimore, Maryland, US, MD
1981	Harvard College, Cambridge, Massachusetts, US, Biochemistry and Molecular Biology, MA, AB

Postgraduate Training

1990-1991	Senior Clinical Fellowship, Endocrinology and Metabolism, Johns Hopkins Hospital, Baltimore, Maryland
1988-1990	Clinical Fellowship, Endocrinology and Metabolism, Johns Hopkins Hospital, Baltimore, Maryland
1986-1988	Clinical Residency, Medicine, Johns Hopkins Hospital, Baltimore, Maryland
1985-1986	Clinical Internship, Medicine, Johns Hopkins Hospital, Baltimore, Maryland

Licenses & Certifications

2023	Washington State Medical License
2023	Georgia Medical License
2023	Tennessee Medical License
2023	Oklahoma Medical License
2023	Arizona Medical License
2023	Mississippi Medical License
2023	Louisiana Medical License
2023	Alabama Medical License
2021	Florida Medical License
1993	Texas Medical License
1991	Endocrinology, Diabetes, and Metabolism, Board Certification
1989	Maryland Medical License
1988	Internal Medicine, Board Certification
1985	New York Medical License

Experience & Service

Faculty Academic Appointments

Associate Professor, Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 2000 - 2005

Associate Professor, Department of Internal Medicine Specialties, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1999 - 2000

Assistant Professor, Department of Medical Specialties, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1993 - 1999

Administrative Appointments/Responsibilities

Senior Vice President, Chief Academic Officer ad interim, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - 2017

Associate Vice Provost, Clinical Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 2014 - 2017

Associate Medical Director, Department of Endocrine Multidisciplinary Center, The University of Texas MD Anderson Cancer Center, Houston, TX, 2012 - 2017

Medical Director, Department of Endocrine Multidisciplinary Center, The University of Texas MD Anderson Cancer Center, Houston, TX, 2006 - 2012

Chief, Department of Section of Endocrine Neoplasia and Hormonal Disorders, Department of Internal Medicine Specialties, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 2000

Department Chair ad interim, Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 2000 - 2004

Rotation Program Coordinator, Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 2000 - 2004

Rotation Program Coordinator, Department of Internal Medicine Specialties, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1999 - 2000

Rotation Program Coordinator, Department of Medical Specialties, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1994 - 1999

Other Professional Positions

Member, Exelixis Thyroid Cancer Virtual Advisory Board, Houston, TX, 2021

Past Chairperson, International Thyroid Oncology Group (ITOG), 2015 - 2016

Member, National Cancer Institute, Rare Tumors TF of the NCI Head & Neck Steering Committee (HNSC), Bethesda, MD, 2014 - 2018

Member, Academic and Community Cancer Research United (ACCRU) Scientific and Administrative Review Committee (SARC), Rochester, MN, 2012 - 2015

Chairman, International Thyroid Oncology Group (ITOG), 2011 - 2015

Treasurer, International Thyroid Oncology Group, 2009 - 2011

Board Member, American Association of Clinical Endocrinologists, Tempe, AZ, 2009 - 2023

Chair, Development Task Force, American Thyroid Association, Falls Church, VA, 2008 - 2010

Member, University of Health Science Center Institute of Molecular Medicine (Search Committee for Director of the Research Center for Metabolic Diseases), Houston, TX, 2006

Member, Differentiated Thyroid Cancer Treatment Guidelines Task Force, American Thyroid Association, 2005 - 2017

Member, Endocrine Society (New Initiatives Committee), 2005 - 2006

Member, Board of Directors, American Thyroid Association, Falls Church, VA, 2003 - 2008

Member, Endocrine Society (Publications Committee), 2003 - 2005

Member, Texas Chapter of American Association of Clinical Endocrinologists (Board of Directors), 2003 - 2005

Member, American Thyroid Association (Strategic Planning Group), 1999 - 2003

Member, American College of Surgeons Oncology Group, 1999 - 2004

Chair, National Comprehensive Cancer Network Guidelines Program (Thyroid Cancer Panel), Philadelphia, PA, 1999 - 2009

Member, National Comprehensive Cancer Network Guidelines Program (Thyroid Cancer Panel), 1998 - 2014

Member, American Thyroid Association (Education Committee), 1998 - 2004

Medical Director, The Thyroid Society for Education and Research, Houston, TX, 1998 - 2001

Member, Human Biological Data Interchange Thyroid Disease Resource (Steering Committee), 1997 - 2000

Member, The Thyroid Society for Education & Research (Board of Directors), 1997 - 2002

Member, American Thyroid Association (Public Health Committee), 1997 - 1998

Member, The Thyroid Society for Education and Research (Medical Advisory Board), 1995 - 2002

Member, Baylor College of Medicine (Scientific Advisory Committee, General Clinical Research Center), Houston, TX, 1993 - 1997

Member, Johns Hopkins University School of Medicine (Scientific Advisory Committee, General Clinical Research Center), Baltimore, MD, 1992 - 1993

Extramural Institutional Committee Activities

Program Committee Member, American Thyroid Association (ATA) Annual Meeting Program Committee, American Thyroid Association (ATA), 2024 - 2027

Member, Reach Executive Committee, The University of Texas MD Anderson Cancer Center, 2024 - 2025

Chair, Clinical Term-Tenure/Term-Tenure Track Hiring Panel, The University of Texas MD Anderson Cancer Center, 2022 - Present

Co-Chair, Data and Safety Monitoring Board, The University of Texas MD Anderson Cancer Center, 2022 - Present

Past Chair, Community of Chairs Leadership Committee, The University of Texas MD Anderson Cancer Center, 2021 - Present

Member, Moonshots Executive Committee, The University of Texas MD Anderson Cancer Center, 2021 - Present

Member, COVID-19 Core Leadership Team (CCLT), The University of Texas MD Anderson Cancer Center, 2020 - Present

Executive Chair, Community of Chairs Leadership Committee, The University of Texas MD Anderson Cancer Center, 2020 - 2021

Chair Elect, Community of Chairs Leadership Committee, The University of Texas MD Anderson Cancer Center, 2019 - 2020

Co-Chair, Executive Scientific Review Committee, The University of Texas MD Anderson Cancer Center, 2019 - 2020

Member, Executive Steering Committee - Accreditation and Regulatory Readiness, The University of Texas MD Anderson Cancer Center, 2019 - 2020

Member, President's Advisory Council, The University of Texas MD Anderson Cancer Center, 2019 - 2022

Member, Electronic Protocol Accrual Auditing Committee (ePAAC), The University of Texas MD Anderson Cancer Center, 2018 - 2019

Co-Chair, Scientific Review Committee (SRC #2), The University of Texas MD Anderson Cancer Center, 2018 - 2020

Member, Community of Chairs/ECFS Chair Accountability Task Force, The University of Texas MD Anderson Cancer Center, 2018 - 2019

Member, Operational Priority #6 Task Force, The University of Texas MD Anderson Cancer Center, 2018 - 2019

Co-Lead, Denials Prevention Task Force, The University of Texas MD Anderson Cancer Center, 2018 - 2019

Budget Committee, Community of Chairs, The University of Texas MD Anderson Cancer Center, 2018 - Present

Member, International Expansion Subgroup Committee, The University of Texas MD Anderson Cancer Center, 2017 - 2018

Member, Liquid Biopsy Executive Committee (LBEC), The University of Texas MD Anderson Cancer Center, 2017 - 2017

Member, Financial Management Task Force, The University of Texas MD Anderson Cancer Center, 2017 - 2017

Member, Executive Clinical Operations Team (ECOT) Finance Subcommittee, The University of Texas MD Anderson Cancer Center, 2017 - 2017

Co-Chair, Community of Chairs Budget Committee, The University of Texas MD Anderson Cancer Center, 2017 - 2017

Member, Search Committee for Chair, Department of Gastroenterology, Hepatology and Nutrition, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, 2016 - 2017

Clinical Researcher Panel Chair, Sabin Family Foundation Fellowship Award, The University of Texas MD Anderson Cancer Center, 2015 - 2018

Member, Making Cancer History Patient Care Award Selection Committee, The University of Texas MD Anderson Cancer Center, 2015 - 2016

Chair, Clinical Department Chair Roles and Responsibilities Task Force, The University of Texas MD Anderson Cancer Center, 2014 - 2016

Member, Search Committee for Faculty, Department of Investigational Cancer Therapeutics (ICT), The University of Texas MD Anderson Cancer Center, 2014 - 2017

Member, Translational Research Strategic Planning Task Force, The University of Texas MD Anderson Cancer Center, 2014 - 2016

Member, Women Faculty Programs' Advisory Committee, The University of Texas MD Anderson Cancer Center, 2014 - 2015

Member, Vice Provost, Clinical and Interdisciplinary Research Search Committee, The University of Texas MD Anderson Cancer Center, 2014 - 2015

Chair, Physician Scientist Faculty Track Task Force, The University of Texas MD Anderson Cancer Center, 2014 - 2017

Member, Institutional Research Executive Committee (IREC), The University of Texas MD Anderson Cancer Center, 2014 - 2017

Member, Executive Steering Committee, eResearch Steering Committee, The University of Texas MD Anderson Cancer Center, 2014 - 2017

Member, Task Force, Clinical Research Billing Process Improvement, The University of Texas MD Anderson Cancer Center, 2014 - 2016

Clinical Innovator Panel Co-Chair, R. Lee Clark Fellows Award, The University of Texas MD Anderson Cancer Center, 2013 - 2014

Member, Enhancing Industry Partnership Working Group, The University of Texas MD Anderson Cancer Center, 2013 - 2014

Vice-Chair, Search Committee for Chair, Department of Diagnostic Radiology, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, 2013 - 2014

Member, The High Impact Clinical Research Support Program (HICRSP), The University of Texas MD Anderson Cancer Center, 2013 - 2017

Member, Electronic Protocol Accrual Auditing Committee (ePAAC), The University of Texas MD Anderson Cancer Center, 2013 - 2017

Member, Charles A. LeMaistre Outstanding Achievement Award in Cancer, The University of Texas MD Anderson Cancer Center, 2013

Co-Chairperson, Clinical Research Committee (CRC) #3, The University of Texas MD Anderson Cancer Center, 2012 - 2017

Member, Endocrine Center Steering Committee, The University of Texas MD Anderson Cancer Center, 2012 - Present

Chair, Vice Provost Clinical Research Advisory Council, The University of Texas MD Anderson Cancer Center, 2012 - 2014

Member, Search Committee for Chair, Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, 2012 - 2012

Member, Institutional Clinical Executive Committee Subcommittee on Clinical Research, The University of Texas MD Anderson Cancer Center, 2011 - 2012

Member, Search Committee for Chair, Department of Diagnostic Radiology, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, 2011 - 2012

Member, Internal Advisory Board, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, 2011 - 2013

Member, Search Committee for Vice President - Clinical Research, The University of Texas MD Anderson Cancer Center, 2010 - 2011

Member, Clinical Council, The University of Texas MD Anderson Cancer Center, 2010 - 2011

Advisory Committee Member, Bone Disease Program of Texas (BDPT), The University of Texas MD Anderson Cancer Center, 2010 - 2016

Member, Clinical Research Financial Reimbursement Committee, The University of Texas MD Anderson Cancer Center, 2009 - 2010

Member, Clinical Research Program Steering Team, The University of Texas MD Anderson Cancer Center, 2009 - 2010

Member, Executive Research Compliance Committee, The University of Texas MD Anderson Cancer Center, 2009 - 2017

Chair, Search Committee for Chair, Department of Gastroenterology, Hepatology, and Nutrition, The University of Texas MD Anderson Cancer Center, 2008 - 2009

Member, Steering Committee, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, 2008 - 2011

Member, Clinical Research Impact Committee, The University of Texas MD Anderson Cancer Center, 2007 - 2008

Chair, Selection Committee for Arceneaux Outstanding Nurse Oncologist Award, The University of Texas MD Anderson Cancer Center, 2007 - 2007

Member, Cancer Survivorship Steering Committee, The University of Texas MD Anderson Cancer Center, 2007 - 2010

Member, Selection Committee for Arceneaux Outstanding Nurse Oncologist Award, The University of Texas MD Anderson Cancer Center, 2006 - 2007

Member, NCI Phase II Contract Committee, The University of Texas MD Anderson Cancer Center, 2006 - 2008

Member, Cultural Principles Working Group, The University of Texas MD Anderson Cancer Center, 2004 - 2005

Member, Steering Committee for M. D. Anderson Cancer Center - Institut Gustave Roussy Collaboration, The University of Texas MD Anderson Cancer Center, 2004 - 2008

Chair, Diabetes Advisory Committee, The University of Texas MD Anderson Cancer Center, 2002 - 2004

Member, Search Committee for Chair, Head & Neck Surgery, The University of Texas MD Anderson Cancer Center, 2002 - 2003

Member, Blue Ribbon Committee for Clinical Research, The University of Texas MD Anderson Cancer Center, 2002 - 2003

Member, Therapeutic Nuclear Medicine Program Steering Committee, The University of Texas MD Anderson Cancer Center, 2002 - 2004

Member, Credentials Committee of the Medical Staff, The University of Texas MD Anderson Cancer Center, 2001 - 2004

Member, Spain Services Implementation Committee, The University of Texas MD Anderson Cancer Center, 2001 - 2005

Member, Research Laboratory Space Subcommittee of the Research Council, The University of Texas MD Anderson Cancer Center, 2001 - 2005

Chair, Graduate Medical Education Committee, The University of Texas MD Anderson Cancer Center, 2001 - 2003

Member, Education Strategic Plan Committee, The University of Texas MD Anderson Cancer Center, 2001 - 2003

Member, Education Council, The University of Texas MD Anderson Cancer Center, 2001 - 2003

Vice Chair, Clinical and Translational Research Center Review Committee, The University of Texas MD Anderson Cancer Center, 2000 - 2001

Member, Faculty Senate, The University of Texas MD Anderson Cancer Center, 1999 - 2000

Member, Organizing Committee, 3rd Foundations of Clinical Cancer Research Symposium, The University of Texas MD Anderson Cancer Center, 1999 - 2000

Vice Chair, Graduate Medical Education Committee, The University of Texas MD Anderson Cancer Center, 1999 - 2001

Chair, Internal Review Subcommittee for Pediatric Hematology and Oncology Training Program, The University of Texas MD Anderson Cancer Center, 1999 - 1999

Co-Chair, Clinical Research Committee II, The University of Texas MD Anderson Cancer Center, 1998 - 2001

Member, Graduate Medical Education Committee, The University of Texas MD Anderson Cancer Center, 1997 - 2005

Member, Clinical Research Committee, The University of Texas MD Anderson Cancer Center, 1995 - 1998

Member, Medical Record Subcommittee of Executive Committee of Medical Staff, The University of Texas MD Anderson Cancer Center, 1995 - 1997

Member, Surveillance Committee, Institutional Review Board, The University of Texas MD Anderson Cancer Center, 1995 - 1998

Alternate Member, Quality Improvement Review Subcommittee of Executive Committee of Medical Staff, The University of Texas MD Anderson Cancer Center, 1994 - 1995

Alternate Member, Medical Record Subcommittee of Executive Committee of Medical Staff, The University of Texas MD Anderson Cancer Center, 1994 - 1995

Member, Clinical Guidelines Working Group, The University of Texas MD Anderson Cancer Center, 1994 - 1995

Editorial Activities

Member, Editorial Board, Endocrine, 2019 - Present

Member, Editorial Board, Endocrine, 2013 - 2017

Guest Editor, Journal of the National Comprehensive Cancer Network, 2005

Member, Editorial Board, Journal of Clinical Endocrinology and Metabolism, 2002 - 2006

Guest Editor, Seminars in Surgical Oncology, 1998

Contributing Editor, Clinical Thyroidology, 1994 - 1998

Honors & Awards

2024	ThyCa Distinguished Service Award, Thyroid Cancer Survivors Association, Inc. (ThyCa)
2024	John Mendelsohn Award for Faculty Leadership, The University of Texas MD Anderson Cancer Center
2010	Outstanding Clinical Publication in Thyroid, 7/2008-12/2009, American Thyroid Association
2007	International Award for Excellence in Published Clinical Research in The Journal of Clinical Endocrinology and Metabolism, The Endocrine Society and Pfizer Inc
2003	Educator of the Month, The University of Texas M. D. Anderson Cancer Center
2002	Fellow, American College of Endocrinology
1992	American Thyroid Association Young Investigator Travel Award, American Thyroid Association
1992	Clinical Associate Physician, NIH General Clinical Research Centers
1982	March of Dimes Research Award, March of Dimes
1978	Edwards Whittaker Scholarship, Harvard College
1978	John Harvard Scholarship, Harvard College

Professional Memberships

International Thyroid Oncology Group (ITOG)

2006 - Present

American Association of Cancer Researchers

2005 - 2009

American Society of Clinical Oncologists

1993 - Present

American Thyroid Association

1993 - Present

Harris County Medical Society

1993 - Present

The Endocrine Society

1993 - Present

American Association of Clinical Endocrinology

1993 - 2023

Selected Presentations & Talks

Local Presentations

2024. "Ask a doctor your questions about papillary and follicular thyroid cancer: Creating clarity before you go home.”. Invited. Thyroid Cancer Survivors Hybrid Conference. Houston, Texas, US.
2019. Evolution of Precision Oncology in Thyroid Carcinoma. Invited. Houston, Texas, US.
2016. Four Decades of Evolving Standards of Cancer. Invited. Internal Medicine and Cancer Survivorship Grand Rounds. Houston, Texas, US.
2015. Internal Medicine and Cancer Survivorship Grand Rounds. Invited. Internal Medicine and Cancer Survivorship Grand Rounds, Clinical Pathologic Conference. Houston, Texas, US.
2014. What's New in Thyroid Cancer Management Guidelines?. Invited. Endocrinology Grand Rounds. Houston, Texas, US.
2013. Kinase Inhibitor Therapy for Thyroid Cancer. Invited. Division of Cancer Medicine, Advances in Oncology Institutional Grand Rounds. Houston, TX, US.
2012. Update in the Management of Thyroid Cancer. Invited. Houston, Texas, US.
2012. Update on Management of Differentiated Thyroid Carcinoma. Invited. Endocrinology Grand Rounds. Houston, Texas, US.
2011. Recent Advances in the Management of Thyroid Cancer. Invited. Division of Internal Medicine and Cancer Survivorship Grand Rounds. Houston, Texas, US.
2011. Targeted Therapy for Thyroid Cancer. Invited. Clinical Trials Faculty Meeting. Houston, Texas, US.
2011. Targeted Therapy for Medullary Thyroid Cancer. Invited. Advances in Oncology Institutional Grand Rounds. Houston, Texas, US.
2010. Clinical Trials in Thyroid Cancer. Invited. Multidisciplinary Head and Neck Clinical Research Conference. Houston, Texas, US.
2010. Introduction/Background: Thyroid Cancer: Disease on the Rise?. Invited. Advances in Oncology Institutional Grand Rounds. Houston, Texas, US.
2009. Current Concepts in Head & Neck Surgery. Invited. Houston, Texas, US.
2009. Novel Chemotherapies for Advanced Thyroid Cancers. Invited. Endocrinology Grand Rounds. Houston, Texas, US.
2009. Quality Improvement. Invited. Internal Medicine and Cancer Survivorship Grand Rounds. Houston, Texas, US.
2003. Management of Differentiated Thyroid Carcinoma. Invited. Nuclear Medicine Conference. Houston, Texas, US.
2001. What's New in the Management of Differentiated Thyroid Carcinoma?. Invited. Endocrinology Grand Rounds. Houston, Texas, US.
2001. Thyroid Disease. Invited. Houston, Texas, US.
2001. New Developments in Management of Differentiated Thyroid Carcinoma. Invited. Internal Medicine Grand Rounds. Galveston, Texas, US.
2001. Treatment of Hypothyroidism. Invited. Houston, Texas, US.
2001. New Approaches to Therapy with Thyroid Hormone and Analogues. Invited. Clinical Pharmacology Consortium of the Texas Medical Center. Houston, Texas, US.
2000. Thyroid Disease in Pregnancy. Invited. Houston, Texas, US.
1999. Evaluation and Management of the Patient with a Thyroid Nodule. Invited. Richmond, Texas, US.
1998. Advances and Challenges in the Management of Thyroid Carcinoma. Invited. Endocrinology Grand Rounds. Galveston, TX, US.
1996. Follow-up and Management of the Patient with Thyroid Cancer. Invited. Houston, Texas, US.
1996. New Developments in Management of Thyroid Carcinoma. Invited. Houston, Texas, US.
1996. Thyroid Disease for the Primary Care Practitioner. Invited. Houston, Texas, US.
1996. Management of Thyroid Neoplasia. Invited. Houston, Texas, US.
1996. Thyroid Nodule Management, Partners in Excellence. Invited. Workshop in Head and Neck. Houston, Texas, US.
1996. Clinical Applications of Thyroid Hormone Analogues. Invited. Houston, Texas, US.
1995. Pathogenesis and Management of Thyroid Carcinoma. Invited. Houston, Texas, US.
1993. (1) Treating Hypothyroidism - The Science and The Art (2) Thyroiditis, Current Concepts in Thyroid Disease. Invited. Baltimore, MD, US.
1993. Radionuclide Scanning in Thyroid Disease. Invited. Baltimore, MD, US.
1993. Thyroid Disease in Pregnancy. Invited. Baltimore, MD, US.
1992. Thyroid Hormone Analogues. Invited. Endocrinology Grand Rounds. Baltimore, MD, US.
1990. Thyroid Carcinoma and Benign Thyroid Disease. Invited. Salisbury, MD, US.

Regional Presentations

2022. Treating Patients with Radioiodine Refractory Thyroid Cancer: TKIs and Beyond. Visiting. Treating Patients with Radioiodine Refractory Thyroid Cancer: TKIs and Beyond. Rochester, MN, US.
2022. Treating Patients With Radioiodine Refractory Thyroid Cancer: TKIs and Beyond. Invited. Treating Patients With Radioiodine Refractory Thyroid Cancer: TKIs and Beyond. Rochester, MN, US.
2022. Treating Patients with Radioiodine Refractory Thyroid Cancer: TKIs and Beyond. Invited. Treating Patients with Radioiodine Refractory Thyroid Cancer: TKIs and Beyond. Bronx, NY, US.
2015. Novel Therapies for Advanced Thyroid Carcinoma. Invited. Endocrinology Grand Rounds. Dallas, Texas, US.
2010. Thyroid Cancer Management. Invited. Dallas, TX, US.
2009. Update on Current Treatment for Thyroid Cancer. Invited. Tumor Board Grand Rounds. Dallas, TX, US.
2006. Update in Thyroid Cancer Management. Invited. 29th Annual Ted Block Memorial Lecturer. Albuquerque, NM, US.
2005. Thyroid Carcinoma. Invited. New Orleans, LA, US.
2004. Hypothyroidism, Hyperthyroidism, and Nodular Thyroid Disease. Invited. Victoria, TX, US.
2003. The Challenge of Consensus Guidelines for Differentiated Thyroid Carcinoma. Invited. Endocrinology Grand Rounds. San Antonio, TX, US.
2001. New Developments in Management of Differentiated Thyroid Carcinoma. Invited. Dallas, TX, US.
2001. Treatment of Differentiated Thyroid Carcinoma. Invited. Alexandria, LA, US.
2000. Art and Science of Thyroid Hormone Therapy. Invited. Baton Rouge, LA, US.
1999. Treatment and Monitoring of Differentiated Thyroid Carcinoma; Thyroid Hormone Suppression Therapy for Thyroid Neoplasia. Invited. 9th Annual Update in Endocrinology. New Orleans, LA, US.
1994. Advances in Management of Thyroid Carcinoma. Invited. Endocrinology Grand Rounds. San Antonio, TX, US.

National Presentations

2025. Uncommon Drivers in Thyroid Malignancies. Poster. American Thyroid Association Annual Meeting 2025. Scottsdale, Arizona, US.
2025. Malignant Struma Ovarii Clinical Characteristics and Outcomes: A Retrospective Tertiary Cancer Center Experience. Invited. American Thyroid Association Annual Meeting 2025. Scottsdale, Arizona, US.
2025. "Outcomes of Brain Metastases from Medullary Thyroid Carcinoma: A Retrospective Cohort Study". Poster. American Thyroid Association Annual Meeting 2025. Scottsdale, Arizona, US.
2025. Educating the Next Generation of Thyroidologists (Planned by Women in Thyroidology). Invited. American Thyroid Association Annual Meeting 2025. Scottsdale, Arizona, US.
2025. Neoadjuvant Treatment with Selpercatinib for RET-Altered Thyroid Cancer: A Multicenter Phase 2 Clinical Trial. Invited. American Thyroid Association Annual Meeting 2025. Scottsdale, Arizona, US.
2025. Surgical management of isthmus-confined papillary thyroid carcinoma: a single institution retrospective cohort study. Poster. American Thyroid Association Annual Meeting 2025. Scottsdale, Arizona, US.
2024. “Intermediate Risk Thyroid Cancer: RAI or no RAI”. Panelist. AMERICAN THYROID ASSOCIATION. Chicago, Illinois, US.
2023. (1) Disorders of Thyroid Function (2) Endocrinology Cases: Thyroid Function (3) Thyroid Nodules and Cancer (4) Endocrinology Cases: Thyroid Nodules. Invited. Primary Care Conferences. Charleston, South Carolina, US.
2023. (1) Anaplastic Thyroid Cancer, Growing Role for Checkpoint Inhibitors (2) Medullary Thyroid Cancer, Screening, and Management (3) Case-based Decision-making in the Management of Thyroid Conditions. Invited. New York City, New York, US.
2023. (1) Disorders of Thyroid Function (2) Endocrinology Cases: Thyroid Function (3) Thyroid Nodules and Cancer (4) Endocrinology Cases: Thyroid Nodules. Invited. Primary Care Conferences. Las Vegas, Nevada, US.
2023. (1) Disorders of Thyroid Function (2) Endocrinology Cases: Thyroid Function (3) Thyroid Nodules and Cancer (4) Endocrinology Cases: Thyroid Nodules. Invited. Primary Care Conferences. Santa Barbara, California, US.
2022. Cabozantinib for radioiodine-refractory differentiated thyroid cancer. Invited. TIROxMDS Virtual Journal Club. Virtual Presentation, US.
2021. Treating Patients with Radioiodine Refractory Thyroid Cancer: TKIs and Beyond. Invited. Endocrine Grand Rounds. Virtual Presentation, US.
2021. Precision Therapy for Advanced Thyroid Cancer. Invited. Charleston, South Carolina, US.
2021. Treatment of Advanced Thyroid Carcinoma. Invited. New York City, New York, US.
2020. **Lecture Postponed Due to COVID-19**. Invited. 45th Samuel Haines’ Lecture. Rochester, Minnesota, US.
2019. Evolution of Precision Oncology in Thyroid Carcinoma. Invited. San Francisco, California, US.
2018. Development and application of cfDNA assays for Ret in medullary thryoid cancer. Invited. Rockville, Maryland, US.
2018. Treating Advanced Thyroid Carcinoma: Moving Beyond (and back to) Radioiodine. Invited. Division of Endocrinology, Diabetes and Bone Diseases Grand Rounds. New York City, New York, US.
2017. Advanced Thyroid Cancer: Beyond (and Back to) Radioiodine. Invited. Oncology Grand Rounds Seminar Series. Washington, DC, US.
2016. Systemic Therapy for Thyroid Neoplasia. Invited. Hematology/Oncology Grand Rounds. Oklahoma City, Oklahoma, US.
2015. Systemic Therapy for Thyroid Neoplasia. Invited. Boston, Massachusetts, US.
2015. Ernest Mazzaferri Visiting Professorship. Visiting. Columbus, Ohio, US.
2015. Systemic Therapy for Medullary Thyroid Carcinoma. Invited. Thyroid Cancer Program Symposium. Chicago, Illinois, US.
2014. Targeted Therapy for Thyroid Carcinoma: What is Being Targeted?. Invited. Division of Hematology and Medical Oncology Grand Rounds. New York City, New York, US.
2014. Targeted Therapy: What Are We Really Targeting. Invited. 10th Biennial Thyroid Disorders 2014: New Diagnostics and Treatments for Clinical Practice Symposium. Washington, DC, US.
2014. Novel Therapies for Medullary Thyroid Cancer. Invited. Endocrine Grand Rounds. Columbus, Ohio, US.
2013. Targeting Chemotherapy for Advanced Thyroid Cancer. Invited. The Sheldon Waldstein Lectureship in Endocrinology. Chicago, Illinois, US.
2012. Targeting Chemotherapy for Advanced Thyroid Cancer. Invited. New York City, NY, US.
2011. Molecular Basis of Thyroid Cancer, Surgery of the Thyroid and Parathyroid Glands. Invited. Boston, MA, US.
2011. (1) Does 131I Actually Reduce the Risk for Mortality or Recurrence? (2) Putting it All Together: What Did I learn and How Does it Apply to My Clinical Practice? (3) What is the Role & the Evidence for EBRT in DTC? (4) 2011 Update on the Management of Anaplastic Thyroid Cancer. Invited. Thyroid, Head and Neck Cancer (THANC) Foundation. White Plains, NY, US.
2010. Novel Therapies for Advanced Thyroid Cancers. Invited. New Hyde Park, NY, US.
2010. Advances in Chemotherapy for Thyroid Carcinoma. Invited. 8th Annual Head and Neck Multidisciplinary Research Workshop. Charleston, SC, US.
2010. Novel Therapeutics for Thyroid Carcinoma. Invited. Bethesda, MD, US.
2010. (1) Advanced Thyroid Cancer - Overview of the Problem (2) What is the Role of EBRT in Advanced Thyroid Cancer. Invited. Thyroid, Head and Neck Cancer (THANC) Foundation. White Plains, NY, US.
2009. Developing Novel Therapeutics for Thyroid Carcinomas. Invited. Sacramento, CA, US.
2009. Targeted Therapy for Thyroid Carcinoma: What is Being Targeted?. Invited. Division of Hematology and Medical Oncology Grand Rounds. New York City, NY, US.
2009. Molecularly Targeted Therapies for Thyroid Cancers. Invited. Brooklyn, NY, US.
2009. Developing Molecularly Targeted Therapies for Thyroid Cancer. Invited. Pittsburgh, PA, US.
2009. (1) Remnant Ablation, Who Needs it and Who Doesn't (2) Clinical Trials: The M. D. Anderson and National Experience. Invited. University of Colorado Denver and State-of-the-Art Management of Patients with Thyroid Nodules and Cancer Symposium. Denver, CO, US.
2009. Molecular Targeted Therapies for Thyroid Cancers. Invited. Endocrine Grand Rounds. San Francisco, CA, US.
2009. Molecularly Targeted Therapy for Advanced Thyroid Carcinoma. Invited. New York City, NY, US.
2009. Molecularly Targeted Therapies for Thyroid Carcinomas. Invited. Endocrine Grand Rounds. Baltimore, MD, US.
2009. William Lees Thyroid Tumor Center Visiting Professor. Visiting. Baltimore, MD, US.
2009. Molecular Targeted Therapies for Advanced Thyroid Cancers. Invited. Tampa, FL, US.
2008. Management of Patients with Refractory Metastatic Thyroid Cancer. Invited. Ernest L. Mazzaferri Thyroid Cancer Conference. Columbus, OH, US.
2008. Developing Novel Therapies for Advanced Thyroid Carcinoma. Invited. Endocrine Grand Rounds. Milwaukee, WI, US.
2008. Developing Novel Therapies for Advanced Thyroid Carcinoma. Invited. Endocrine Grand Rounds. Boston, MA, US.
2007. Farahe Maloof Memorial Lecturer. Invited. Farahe Maloof Memorial Lecturer. Boston, MA, US.
2007. Treatment of Advanced Thyroid Carcinoma. Invited. Endocrinology Grand Rounds. Philadelphia, PA, US.
2007. Thyroid Cancer Case Discussion. Invited. Endocrinology Grand Rounds. Philadelphia, PA, US.
2007. (1) Novel Therapies for Undifferentiated and Anaplastic Thyroid Carcinoma (2) Debate: The Case for Treating Anaplastic Thyroid Carcinoma with Chemoradiation Without Surgery. Invited. Division of Hematology and Medical Oncology Grand Rounds. New York City, NY, US.
2007. Treatment of Advanced and Metastatic Thyroid Carcinoma. Invited. Endocrinology Grand Rounds. Chicago, IL, US.
2006. (1) Treating Low Risk Differentiated Thyroid Carcinoma (2) Treating Advanced Thyroid Carcinoma. Invited. Oncology and Hematology Grand Rounds. Atlanta, GA, US.
2006. Drug Development in Thyroid Cancer. Invited. Drug Development & Pharmacogenomics Academy Lecturer. Atlanta, GA, US.
2006. (1) Present and Future Strategies for Medical Therapy in Aggressive, Differentiated Thyroid Cancer (2) Current Management of Anaplastic Thyroid Carcinoma. Invited. Thyroid, Head and Neck Cancers (THANC) Foundation. New York City, NY, US.
2006. Management of High Risk Patients with Thyroid Carcinoma. Invited. Endocrinology Grand Rounds. New York City, NY, US.
2005. Management of High Risk Patients with Thyroid Carcinoma. Invited. Denver, CO, US.
2005. Management of Patients with Thyroid Carcinoma. Invited. Charleston, SC, US.
2005. Treatment of Advanced Thyroid Carcinoma Beyond Slash and Burn,. Invited. San Francisco,, CA, US.
2004. Managing Advanced Thyroid Carcinoma Beyond Slash and Burn. Invited. Providence, RI, US.
2004. Managing Advanced Thyroid Carcinoma Beyond Slash and Burn. Invited. Chicago, IL, US.
2004. Experimental Therapeutics for Advanced Thyroid Carcinoma. Invited. Endocrinology Research Conference. Baltimore, MD, US.
2004. Managing Advanced Thyroid Carcinoma Beyond Slash and Burn. Invited. Endocrinology Grand Rounds. Miami, FL, US.
2003. Treatment of Differentiated Thyroid Carcinoma: Beyond Slash and Burn. Invited. Newark, NJ, US.
2001. What's New in the Management of Differentiated Thyroid Carcinoma?. Invited. Internal Medicine Grand Rounds. Oak Lawn, IL, US.
2000. New Approaches to the Management of Differentiated Thyroid Carcinoma. Invited. Birmingham, AL, US.
2000. New Approaches to the Management of Differentiated Thyroid Carcinoma. Invited. Endocrinology Grand Rounds. Worcester, MA, US.
2000. Art and Science of Thyroid Hormone Therapy; Endocrinology Research Conference: Retinoids and the Thyroid. Invited. Internal Medicine Grand Rounds. Washington, DC, US.
2000. Retinoids and the Thyroid. Invited. , Endocrinology Grand Rounds. Baltimore, MD, US.
2000. Art and Science of Thyroid Hormone Therapy. Invited. Internal Medicine Grand Rounds. Cincinnati, OH, US.
2000. Advances in the Management of Differentiated Thyroid Carcinoma. Invited. Nashville, TN, US.
1999. (1) Advances in the Management of Differentiated Thyroid Carcinoma (2) Thyroid Cancer Case Presentations. Invited. Louisville, KY, US.
1999. Controversies in Management of Thyroid Carcinoma. Invited. Memphis, TN, US.
1997. Advances and Challenges in the Management of Thyroid Carcinoma. Invited. Atlanta, GA, US.
1997. Advances and Challenges in the Management of Thyroid Carcinoma. Invited. Bethesda, MD, US.
1996. New Developments in Management of Differentiated Thyroid Carcinoma. Invited. Hormones and Cancer Research Seminar: Evaluation of Thyroid Hormone Analogues. Denver, CO, US.
1996. Clinical Applications of Thyroid Hormone Analogues. Invited. Endocrinology Grand Rounds. Baltimore, MD, US.

International Presentations

2020. Recent Controversies and Advances in Radioactive Iodine Refractory Thyroid Cancer. Invited. Montreal, CA.
2020. Management of RAI‐refractory Thyroid Cancer. Invited. Montreal, CA.
2020. Treatment of Differentiated Thyroid Carcinoma. Invited. Montreal, CA.
2020. **Lecture Canceled Due to COVID-19**. Invited. Romulo Ayuso’s Memorial Lecture in Thyroid Cancer. San Juan, PR.
2019. Visiting Professor in Endocrinology. Visiting. Naples, IT.
2019. Visiting Professor in Internal Medicine. Visiting. Rome, IT.
2019. New Therapies of Aggressive Thyroid Cancer. Invited. Pisa, IT.
2018. Metastatic MTC: Current and New Treatments. Invited. Sao Paulo, BR.
2017. Visiting Professor in Internal Medicine. Visiting. Rome, IT.
2013. Visiting Professor in Thyroidology. Visiting. Rome, IT.
2013. Thyroid Cancer: A Model for Cancer Biology. Invited. Rome, IT.
2013. Targeting Chemotherapy for Advanced Thyroid Cancer. Invited. Berlin, DE.
2013. Targeted Therapy for Medullary Thyroid Cancer. Invited. Rome, IT.
2011. Management of Advanced Differentiated Thyroid Cancer: results of therapeutic trials and new perspectives. Invited. Rome, IT.
2009. Molecularly Targeted Therapies for Metastatic Thyroid Carcinoma/Postoperative Radioiodine: Who Needs It?. Invited. 2nd Annual Ted Wilkins Distinguished Lectureship. Vancouver, CA.
2008. Novel Therapies for Advanced Thyroid Cancers. Invited. Endocrine Grand Rounds. Rome, IT.
2006. (1) Diagnostic and Therapeutic Issues in Thyroid Cancer (2) Meet the Professor-Thyroid Nodules. Invited. Canada International Endocrine Symposium. Toronto, CA.
1998. Indications for Intervention in Thyroid Nodular Disease. Invited. Toronto, CA.

Formal Peers

2016. Intensive Review of Endocrinology and Metabolism, US.
2014. Anti-Angiogenic TKI's for Thyroid Cancer. San Diego, CA, US.
2011. Advances in Thyroid Cancer. Invited. Boston, MA, US.
2009. Chemotherapy Options for Metastatic Thyroid Cancer: An Update. Invited. Atlanta, GA, US.
1998. Follow-up and Management of the Patient with Thyroid Cancer. Invited. Houston, TX, US.
1998. Diagnosis and Management of Hypothyroidism and Thyroid Nodules. Invited. Richmond, TX, US.

Less

Grant & Contract Support

Date:	2020 - 2025
Title:	Thyroid Cancer SPORE: Approaches to optimize thyroid cancer detection and therapy
Funding Source:	NIH/NCI
Role:	Admin Core Co-Lead / CEP Co-Director
ID:	1 P50 CA244123-01

Date:	2020
Title:	Active Monitoring vs. Surgery for Thyroid Cancer: Evidence to Inform Patient Choice and Implementation
Funding Source:	Memorial Sloan Kettering Cancer Center
Role:	Collaborator

Date:	2019 - Present
Title:	Phase III trial of cabozantinib versus placebo in radioiodine-refractory differentiated thyroid carcinoma
Funding Source:	Exelixis
Role:	Principal Investigator-MDACC
ID:	XL184-311

Date:	2013 - 2019
Title:	The Ohio State University and MD Anderson Cancer Center Thyroid Cancer SPORE
Funding Source:	NIH/NCI
Role:	Project 4 Co-Leader; DRP Co-Leader
ID:	P50 CA168505

Date:	2013 - 2024
Title:	Cancer Center Support Grant - Head and Neck Cancer Program (PP8)
Funding Source:	NIH/NCI
Role:	Co-Program Leader
ID:	2 P30 CA016672

Date:	2011 - 2013
Title:	National Thyroid Cancer Treatment Cooperative Study Group
Funding Source:	Pfizer
Role:	PI

Date:	2009 - 2010
Title:	Circulating Tumor Cells in Thyroid Carcinomas
Funding Source:	V Foundation for Cancer Research
Role:	PI
ID:	2008-0847

Date:	2008 - 2017
Title:	National Thyroid Cancer Treatment Cooperative Study Group
Funding Source:	Genzyme Corporation
Role:	PI
ID:	PCR04-0451

Date:	2004 - 2013
Title:	Phase II Study of Bortezomib for Metastatic Thyroid Carcinoma
Funding Source:	NIH/NCI
Role:	Sub-Investigator
ID:	N01CM17003

Date:	2004 - 2005
Title:	Phase II Study of Decitabine for Radioiodine-Resistant Thyroid Carcinoma
Funding Source:	NIH/NCI
Role:	Translational Research Initiative Principal Investigator
ID:	N01CM17003

Date:	2004 - 2013
Title:	Phase II Study of Decitabine for Radioiodine-Resistant Thyroid Carcinoma
Funding Source:	NIH/NCI
Role:	Sub-Investigator
ID:	N01CM17003

Selected Publications

Peer-Reviewed Articles

Marcia S. Brose, Bhumsuk Keam, Jolanta Krajewska, Ana O. Hoff, Fernanda Vaisman, Chia-Chi Lin, Erika Hitre, Daniel W. Bowles, Bruce Robinson, Sherman SI, Nuttapong Ngamphaiboon, Xiang Guo, Andrew Simmons, Denise Williamson, Svetlana Andrianova, Nicholas Berry, Jaume Capdevila. Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer after prior vascular endothelial growth factor receptor-targeted therapy (COSMIC-311): outcomes by BRAF status. Front. Oncol 16, 2026. e-Pub 2026.
Hamidi S, Subbiah V, Cabanillas ME, Sherman SI, Vodopivec DM, Dadu R, Hu MI. Acquired Driver Fusions as a Mechanism of Resistance to Selective RET Inhibitors in Advanced Medullary Thyroid Carcinoma. JCO Precis Oncol 10:e2400900, 2026. e-Pub 2026. PMID: 41719512.
Brinkman, AK, Salami-Henry, AY, Aaron-Brija, LA, Hannah, FM, Hu, MI, Hwang, LL, Patel, RP, Rollins, JL, Sherman, SI, Williams, JK, Kikani, NJ, Weitzman, SP. Increasing Access and Quality Care for Immune Checkpoint Inhibitor–Related Thyroid Dysfunction. JCO Oncology Practice 19, 2025. e-Pub 2025. PMID: 41418091.
Bagheri-Yarmand R, Pagnotti GM, Kidd JL, Ramirez DA, Trivedi T, Guerra L, Wang Z, Cruz LM, Moehle JM, Jebaraj YS, Wan X, Song JH, Bassett R, Lin SH, Hu MI, Sherman SI, Hofmann MC, Guise TA. Activating RET Mutations Promotes Osteoblastic Bone Metastases in Medullary Thyroid Cancer. bioRxiv, 2025. e-Pub 2025. PMID: 40791374.
Li, S, Zheng, G, Xu, L, Goswami, M, Zafereo, M, Sherman, SI, Li, G, Sturgis, EM, Wang, RJ. Polygenic Score for Clinicopathologic Features and Survival Outcomes in Papillary Thyroid Carcinoma. JAMA Otolaryngology - Head and Neck Surgery 151(2):113-120, 2025. e-Pub 2025. PMID: 39602114.
Marczyk, VR, Fazeli, S, Dadu, R, Busaidy, NL, Iyer, PC, Hu, MI, Sherman, SI, Hamidi, S, Hosseini, SM, Williams, MD, Ahmed, S, Routbort, MJ, Luthra, R, Roy Chowdhuri, S, San Lucas, FA, Patel, KP, Hong, DS, Zafereo, M, Wang, RJ, Maniakas, A, Waguespack, SG, Cabanillas, ME. NTRK Fusion-Positive Thyroid Carcinoma. JCO Precision Oncology 9, 2025. e-Pub 2025. PMID: 39983078.
Hamidi, S, Yedururi, S, Hu, MI, Busaidy, NL, Sherman, SI, Jimenez, C, Grubbs, EG, Maniakas, A, Zafereo, M, Subbiah, V, Waguespack, SG. Efficacy and Safety of Selective RET Inhibitors in Patients with Advanced Hereditary Medullary Thyroid Carcinoma. Thyroid 35(1):6-17, 2025. e-Pub 2025. PMID: 39630530.
Wu, WY, Luke, BT, Wu, XC, Lee, JJ, Yi, Y, Okpechi, SC, Gause, B, Mehta, PB, Sherman, SI, Ochoa, AC, Dmitrovsky, E, Liu, X. Glycemic control in diabetic patients improved overall lung cancer survival across diverse populations. JNCI Cancer Spectrum 8(5), 2024. e-Pub 2024. PMID: 39270065.
Wu YH, Luke B, Wu XC, Lee J, Yi Y, Okpechi S, Gause B, Mehta P, Sherman SI, Ochoa A, Dmitrovsky D, Liu X. Glycemic Control in Diabetic Patients Improved Overall Lung Cancer Survival across Diverse Populations. National Cancer Institute (JNCI) Cancer Spectrum. e-Pub 2024.
Shirali, a, Hu, M, Chiang, Y, Graham, P, Fisher, S, Sosa, J, Perrier, N, Brown, S, Holla, V, Dadu, R, Busaidy, N, Sherman, S, Cabanillas, M, Waguespack, S, Zafereo, M, Grubbs, E. Next-Generation Sequencing in Sporadic Medullary Thyroid Cancer Patients: Mutation Profile and Disease Aggressiveness. J of the Endocrine Society 8(6):bvae048, 2024. e-Pub 2024. PMID: 38660141.
Subbiah, V, Gouda, M, Iorgulescu, JB, Dadu, R, Patel, K, Sherman, S, cabanillas, M, Hu, M, Castellanos, L, Amini, B, Meric-Bernstam, F, Shen, T, Wu, J. Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer. NPJ Precis Oncol 8(1):62, 2024. e-Pub 2024. PMID: 38438731.
Capdevila, J, Krajewski, J, Hernando, J, Robinson, B, Sherman, Jarzab S, B, Lin, CC, Vaisman, F, Hoff, A, Hitre, E, Bowles, D, Williamson, D, Levytskyy, R, Oliver, J, Keam, B, Brose, M. Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study. Thyroid 34(3):347-359, 2024. e-Pub 2024. PMID: 38062732.
Lazure, P, Sireci, A, Subbiah, V, Murray, S, Grohe, C, Sherman, SI, Kelly, E, Bubach, P, Peloquin, S. Challenges in diagnosis and biomarker testing for RET-altered lung and thyroid cancer care: an international mixed-method study. BMC Medical Education 23(1):410, 2023. e-Pub 2023. PMID: 37277734.
Murray, S, Subbiah, V, Sherman, SI, Peloquin, S, Sireci, A, Grohe, C, Bubach, P, Lazure, P. Challenges in the care of patients with RET-altered thyroid cancer: a multicountry mixed-methods study. Thyroid Res 16(1):22, 2023. e-Pub 2023. PMID: 37574538.
Brose, MS, Robinson, BG, Sherman, SI, Jarzab, B, Lin, C, Vaisman, F, Hoff, AO, Hitre, E, Bowles, DW, Sen, S, Oliver, JW, Banerjee, K, Keam, B, Capdevila, J. Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial. Cancer 128(24):4203-4212, 2022. e-Pub 2022. PMID: 36259380.
Kiyota N, Tahara M, Robinson B, Schlumberger M, Sherman SI, Leboulleux S, Lee EK, Suzuki T, Ren M, Fushimi K, Wirth LJ. Impact of Baseline Tumor Burden on Overall Survival in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Treated With Lenvatinib in the SELECT Global Phase 3 Trial. Cancer 128(12):2281-2287, 2022. e-Pub 2022. PMID: 35380178.
Khalil M, Zafereo M, Gule-Monroe M, Sherman SI, Bell D. Non-functional water clear cell parathyroid carcinoma masquerading as medullary thyroid carcinoma. Ann Diagn Pathol 54:151791, 2021. e-Pub 2021. PMID: 34293707.
Brose MS, Robinson B, Sherman SI, Krajewska J, Lin CC, Vaisman F, Hoff AO, Hitre E, Bowles DW, Hernando J, Faoro L, Banerjee K, Oliver JW, Keam B, Capdevila J. Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 22(8):1126-1138, 2021. e-Pub 2021. PMID: 34237250.
Taylor MH, Takahashi S, Capdevila J, Tahara M, Leboulleux S, Kiyota N, Dutcus CE, Xie R, Robinson B, Sherman S, Habra MA, Elisei R, Wirth LJ. Correlation of Performance Status and Neutrophil-Lymphocyte Ratio With Efficacy in Radioiodine-Refractory Differentiated Thyroid Cancer Treated With Lenvatinib. Thyroid 31(8):1226-1234, 2021. e-Pub 2021. PMID: 33637020.
Wirth LJ, Brose MS, Sherman EJ, Licitra L, Schlumberger M, Sherman SI, Bible KC, Robinson B, Rodien P, Godbert Y, De La Fouchardiere C, Newbold K, Nutting C, Misir S, Xie R, Almonte A, Ye W, Cabanillas ME. Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer. J Clin Oncol 39(21):2359-2366, 2021. e-Pub 2021. PMID: 33961488.
Bagheri-Yarmand R, Dadu R, Ye L, Shiny Jebaraj Y, Martinez JA, Ma J, Tarapore RS, Allen JE, Sherman SI, Williams MD, Gagel RF. ONC201 shows anti-cancer activity against medullary thyroid cancer via transcriptional inhibition of RET, VEGFR2, and IGFBP2. Mol Cancer Ther 20(4):665-675, 2021. e-Pub 2021. PMID: 33536187.
Cascone T, Sacks RL, Subbiah IM, Drobnitzky N, Piha-Paul SA, Hong DS, Hess KR, Amini B, Bhatt T, Fu S, Naing A, Janku F, Karp D, Falchook GS, Conley AP, Sherman SI, Meric-Bernstam F, Ryan AJ, Heymach JV, Subbiah V. Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study. ESMO Open 6(2):100079, 2021. e-Pub 2021. PMID: 33721621.
Nies M, Vassilopoulou-Sellin R, Bassett RL, Yedururi S, Zafereo ME, Cabanillas ME, Sherman SI, Links TP, Waguespack SG. Distant metastases from childhood differentiated thyroid carcinoma: clinical course and mutational landscape. J Clin Endocrinol Metab 106(4):e1683-e1697, 2021. e-Pub 2021. PMID: 33382403.
Yin N, Sherman SI, Pak Y, Litofsky DR, Gianoukakis AG, Study Group NTCTC. The De Novo Detection of Anti-Thyroglobulin Antibodies and Differentiated Thyroid Cancer Recurrence. Thyroid 30(10):1490-1495, 2020. e-Pub 2020. PMID: 32228151.
Hegde A, Andreev-Drakhlin AY, Roszik J, Huang L, Liu S, Hess K, Cabanillas M, Hu MI, Busaidy NL, Sherman SI, Dadu R, Grubbs EG, Ali SM, Lee J, Elamin YY, Simon GR, Blumenschein GR, Papadimitrakopoulou VA, Hong D, Meric-Bernstam F, Heymach J, Subbiah V. Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies. ESMO Open 5(5):e000799, 2020. e-Pub 2020. PMID: 33097651.
Jozaghi Y, Zafereo ME, Perrier ND, Wang JR, Grubbs E, Gross ND, Fisher S, Sturgis EM, Goepfert RP, Lai SY, Best C, Busaidy NL, Cabanillas ME, Dadu R, Gagel RF, Habra MA, Hu MI, Jimenez C, Sherman SI, Thosani S, Varghese J, Waguespack SG, Weitzman S, Ying AK, Graham PH. Endocrine surgery in the Coronavirus disease 2019 pandemic: Surgical Triage Guidelines. Head Neck 42(6):1325-1328, 2020. e-Pub 2020. PMID: 32437031.
Kurzrock R, Ball DW, Zahurak ML, Nelkin BD, Subbiah V, Ahmed S, O'Connor A, Karunsena E, Parkinson RM, Bishop JA, Ha Y, Sharma R, Gocke CD, Zinner R, Rudek MA, Sherman SI, Azad NS. A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers. Clin Cancer Res 25(18):5475-5484, 2019. e-Pub 2019. PMID: 31186313.
Kutahyalioglu M, Nguyen HT, Kwatampora L, Clarke C, Silva A, Ibrahim E, Waguespack SG, Cabanillas ME, Jimenez C, Hu MI, Sherman SI, Kopetz S, Broaddus R, Dadu R, Wanland K, Williams M, Zafereo M, Perrier N, Busaidy NL. Genetic profiling as a clinical tool in advanced parathyroid carcinoma. J Cancer Res Clin Oncol 145(8):1977-1986, 2019. e-Pub 2019. PMID: 31309300.
Khan SA, Ci B, Xie Y, Gerber DE, Beg MS, Sherman SI, Cabanillas ME, Busaidy NL, Burtness BA, Heilmann AM, Bailey M, Ross JS, Sher DJ, Ali SM. Unique mutation patterns in anaplastic thyroid cancer identified by comprehensive genomic profiling. Head Neck 1(6):1928-1934, 2019. e-Pub 2019. PMID: 30758123.
Hurst Z, Liyanarachchi S, He H, Brock P, Sipos J, Nabhan F, Kebebew E, Green P, Cote GJ, Sherman S, Walker CJ, Chang YS, Xue S, Hollingsworth B, Li W, Genutis L, Menq E, de la Chapelle A, Jhiang SM. Risk Haplotypes Uniquely Associated with Radioiodine Refractory Thyroid Cancer Patients of High African Ancestry. Thyroid 29(4):530-539, 2019. e-Pub 2019. PMID: 30654714.
Bagheri-Yarmand R, Sinha KM, Li L, Lu Y, Cote GJ, Sherman SI, Gagel RF. Combinations of Tyrosine Kinase Inhibitor and ERAD Inhibitor Promote Oxidative Stress-Induced Apoptosis through ATF4 and KLF9 in Medullary Thyroid Cancer. Mol Cancer Res 17(3):751-760, 2019. e-Pub 2019. PMID: 30552230.
Tam S, Boonsripitayanon M, Amit M, Fellman BM, Li Y, Busaidy N, Cabanillas M, Dadu R, Sherman SI, Waguespack SG, Williams MD, Goepfert RP, Gross ND, Perrier N, Sturgis E, Zafereo M. Survival in Differentiated Thyroid Cancer: Comparing the AJCC Cancer Staging 7th and 8th editions. Thyroid(10):1301-1310, 2018. e-Pub 2018. PMID: 30141373.
Jaber T, Waguespack SG, Cabanillas ME, Elbanan M, Vu T, Dadu R, Sherman SI, Amit M, Santos EB, Zafereo M, Busaidy NL. Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive Iodine. J Clin Endocrinol Metab 103(10):3698-3705, 2018. e-Pub 2018. PMID: 30032208.
Subbiah V, Sen S, Hess K, Janku F, Hong DS, Khatua S, Karp D, Munoz J, Falchook GS, Groisberg R, Tsimberidou AM, Sherman SI, Hwu P, Meric-Bernstam F. Phase I Study of the BRAF Inhibitor Vemurafenib in Combination With the Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With BRAF-Mutated Malignancies. JCO Precision Oncology, 2018. e-Pub 2018. PMID: 32913986.
Wirth LJ, Tahara M, Robinson B, Francis S, Brose MS, Habra MA, Newbold K, Kiyota N, Dutcus CE, Mathias E, Guo M, Sherman SI, Schlumberger M. Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT). Cancer 124(11):2365-2372, 2018. e-Pub 2018. PMID: 29656442.
Romero Arenas MA, Rich TA, Hyde SM, Busaidy NL, Cote GJ, Hu MI, Gagel RF, Gidley PW, Jimenez C, Kupferman ME, Peterson SK, Sherman SI, Ying A, Bassett RL, Waguespack SG, Perrier ND, Grubbs EG. Recontacting Patients with Updated Genetic Testing Recommendations for Medullary Thyroid Carcinoma and Pheochromocytoma or Paraganglioma. Ann Surg Oncol 25(5):1395-1402, 2018. e-Pub 2018. PMID: 29427212.
Giordano TJ, Haugen BR, Sherman SI, Shah MH, Caoili EM, Koenig RJ. Pioglitazone Therapy of PAX8-PPARy Fusion Protein Thyroid Carcinoma. J Clin Endocrinol Metab 103(4):1277-1281, 2018. e-Pub 2018. PMID: 29373711.
Hegedüs L, Sherman SI, Tuttle RM, von Scholten BJ, Rasmussen S, Karsbøl JD, Daniels GH, Trial Investigators LPCOBOTL. No Evidence of Increase in Calcitonin Concentrations or Development of C-Cell Malignancy in Response to Liraglutide for Up to 5 Years in the LEADER Trial. Diabetes Care 41(3):620-622, 2018. e-Pub 2018. PMID: 29279300.
Sherman SI, Kloos RT, Tuttle RM, Pontecorvi A, Völzke H, Harper K, Vance C, Alston JT, Usborne AL, Sloop KW, Lakshmanan M. No calcitonin change in a person taking dulaglutide diagnosed with pre-existing medullary thyroid cancer. Diabet Med 35(3):381-385, 2018. e-Pub 2018. PMID: 28755389.
Schlumberger M, Elisei R, Müller S, Schöffski P, Brose M, Shah M, Licitra L, Krajewska J, Kreissl MC, Niederle B, Cohen EEW, Wirth L, Ali H, Clary DO, Yaron Y, Mangeshkar M, Ball D, Nelkin B, Sherman S. Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma. Ann Oncol 28(11):2813-2819, 2017. e-Pub 2017. PMID: 29045520.
Cote GJ, Evers C, Hu MI, Grubbs EG, Williams MD, Hai T, Duose DY, Houston MR, Bui JH, Mehrotra M, Waguespack SG, Busaidy NL, Cabanillas ME, Habra MA, Luthra R, Sherman SI. Prognostic Significance of Circulating RET M918T Mutated Tumor DNA in Patients with Advanced Medullary Thyroid Carcinoma. J Clin Endocrinol Metab 102(9):3591-3599, 2017. e-Pub 2017. PMID: 28911154.
Tahara M, Schlumberger M, Elisei R, Habra MA, Kiyota N, Paschke R, Dutcus CE, Hihara T, McGrath S, Matijevic M, Kadowaki T, Funahashi Y, Sherman SI. Exploratory Analysis of Biomarkers Associated with Clinical Outcomes from the Study of Lenvatinib in Differentiated Cancer of the Thyroid. Eur J Cancer 75:213-221, 2017. e-Pub 2017. PMID: 28237867.
Haddad RI, Schlumberger M, Wirth LJ, Sherman EJ, Shah MH, Robinson B, Dutcus CE, Teng A, Gianoukakis AG, Sherman SI. Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT Trial and their association with survival outcomes. Endocrine 56(1):121-128, 2017. e-Pub 2017. PMID: 28155175.
Tang C, Sherman SI, Price M, Weng J, Davis SE, Hong DS, Yao JC, Buzdar A, Wilding G, Lee JJ. Clinical trial characteristics and barriers to participant accrual: The MD Anderson cancer center experience over 30 years, a historical foundation for trial improvement. Clin Cancer Res 23(6):1414-1421, 2017. e-Pub 2017. PMID: 28275168.
Xu JY, Murphy WA, Milton DR, Jimenez C, Rao SN, Habra MA, Waguespack SG, Dadu R, Gagel RF, Ying AK, Cabanillas ME, Weitzman SP, Busaidy NL, Sellin RV, Grubbs E, Sherman SI, Hu MI. Bone Metastases and Skeletal-Related Events in Medullary Thyroid Carcinoma. J Clin Endocrinol Metab 101(12):4871-4877, 2016. e-Pub 2016. PMID: 27662441.
Sherman SI, Clary DO, Elisei R, Schlumberger MJ, Cohen EE, Schöffski P, Wirth LJ, Mangeshkar M, Aftab DT, Brose MS. Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer. Cancer 122(24):3856-3862, 2016. e-Pub 2016. PMID: 27525386.
Xu JY, Grubbs EG, Waguespack SG, Jimenez C, Gagel RF, Sosa JA, Sellin RV, Dadu R, Hu MI, Trotter CS, Jackson M, Rich TA, Hyde SM, Sherman SI, Cote GJ. Medullary Thyroid Carcinoma Associated with Germline RET(K666N) Mutation. Thyroid 26(12):1744-1751, 2016. e-Pub 2016. PMID: 27673361.
Xu JY, Handy B, Michaelis CL, Waguespack SG, Hu MI, Busaidy N, Jimenez C, Cabanillas ME, Fritsche HA, Cote GJ, Sherman SI. Detection and Prognostic Significance of Circulating Tumor Cells in Patients with Metastatic Thyroid Cancer. J Clin Endocrinol Metab 101(11):4461-4467, 2016. e-Pub 2016. PMID: 27575943.
Robinson B, Schlumberger M, Wirth LJ, Dutcus CE, Song J, Taylor MH, Kim SB, Krzyzanowska MK, Capdevila J, Sherman SI, Tahara M. Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid Cancer. J Clin Endocrinol Metab 101(11):4103-4109, 2016. e-Pub 2016. PMID: 27548104.
Brose MS, Cabanillas ME, Cohen EE, Wirth LJ, Riehl T, Yue H, Sherman SI, Sherman EJ. Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. Lancet Oncol 17(9):1272-1282, 2016. e-Pub 2016. PMID: 27460442.
Falchook GS, Rady P, Konopinski JC, Busaidy N, Hess K, Hymes S, Nguyen HP, Prieto VG, Bustinza-Linares E, Lin Q, Parkhurst KL, Hong DS, Sherman S, Tyring SK, Kurzrock R. Merkel Cell Polyomavirus and Human Papilloma Virus in Proliferative Skin Lesions Arising in Patients Treated with BRAF Inhibitors Archives of Dermatological Research. Archives of Dermatological Research 308(5):357-365, 2016. e-Pub 2016. PMID: 27098388.
Evers C, Duose DY, Mehrotra M, Hai T, Houston MR, Hu PC, Luthra R, Sherman SI, Cote CJ. Liquid Biopsy: Comparison of Mutation Detection Methods for Measurement of RET M918T Circulating Cell-Free DNA in Medullary Thyroid Cancer Patients. Cancer Genetics 209(6):287, 2016. e-Pub 2016.
Schlumberger M, Jarzab B, Cabanillas ME, Robinson B, Pacini F, Ball DW, McCaffrey J, Newbold K, Allison R, Martins RG, Licitra LF, Shah MH, Bodenner D, Elisei R, Burmeister L, Funahashi Y, Ren M, O'Brien JP, Sherman SI. A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer. Clin Canc Res 22(1):44-53, 2016. e-Pub 2016. PMID: 26311725.
Haugen BR, Alexander EK, Bible KC, Doherty G, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 26(1):1-133, 2016. e-Pub 2016. PMID: 26462967.
Heilmann AM, Subbiah V, Wang K, Sun JX, Elvin JA, Chmielecki J, Sherman SI, Murthy R, Busaidy NL, Subbiah I, Yelensky R, Nangia C, Vergilio JA, Khan SA, Erlich RL, Lipson D, Ross JS, Miller VA, Shah MH, Ali SM, Stephens PJ. Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma. Oncology 90(6):339-46, 2016. e-Pub 2016. PMID: 27207748.
Kiyota N, Schlumberger M, Muro K, Ando Y, Takahashi S, Yasukazu K, Wirth L, Robinson B, Sherman S, Suzuki T, Fujino K, Gupta A, Hayato S, Tahara M. Subgroup analysis of Japanese patients in a phase 3 study of Lenvatinib in radioiodine-refractory differentiated thyroid cancer. Cancer Science Journal 106(12):1714-21, 2015. e-Pub 2015. PMID: 26426092.
Dadu R, Hu MI, Cleeland C, Busaidy NL, Habra M, Waguespack SG, Sherman SI, Ying A, Fox P, Cabanillas ME. Efficacy of the natural clay, calcium aluminosilicate anti-diarrheal, in reducing medullary thyroid cancer-related diarrhea and its effects on quality of life: A pilot study. Thyroid 25(10):1085-90, 2015. e-Pub 2015. PMID: 26200040.
McLeod DS, Jonklaas J, Brierley JD, Ain KB, Cooper DS, Fein HG, Haugen BR, Ladenson PW, Magner J, Ross DS, Skarulis MC, Steward DL, Xing M, Litofsky DR, Maxon HR, Sherman SI. Reassessing the NTCTCS Staging Systems for Differentiated Thyroid Cancer, Including Age at Diagnosis. Thyroid 25(10):1097-1105, 2015. e-Pub 2015. PMID: 26203804.
Carhill AA, Litofsky DR, Ross DS, Jonklaas J, Cooper DS, Brierley JD, Ladenson PW, Ain KB, Fein HG, Haugen BR, Magner J, Skarulis MC, Steward DL, Xing M, Maxon HR, Sherman SI. Long-term outcomes following therapy in differentiated thyroid carcinoma: NTCTCS registry analysis 1987-2012. J Clin Endocrinol Metab 100(9):3270-3279, 2015. e-Pub 2015. PMID: 26171797.
Cabanillas ME, Schlumberger M, Jarzab B, Martins RG, Pacini F, Robinson B, McCaffrey JC, Shah MH, Bodenner DL, Topliss D, Andresen C, O'Brien JP, Ren M, Funahashi Y, Allison R, Elisei R, Newbold K, Licitra LF, Sherman SI, Ball DW. A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment. Cancer 121(16):2749-56, 2015. e-Pub 2015. PMID: 25913680.
Carhill AA, Litofsky DR, Sherman SI. Unique characteristics and outcomes of patients diagnosed with both primary thyroid and primary renal cell carcinoma. Endocr Pract 21(5):461-7, 2015. e-Pub 2015. PMID: 25536972.
Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO, Gianoukakis AG, Kiyota N, Taylor MH, Kim SB, Krzyzanowska MK, Dutcus CE, de las Heras B, Zhu J, Sherman SI. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 372(7):621-630, 2015. e-Pub 2015. PMID: 25671254.
Falchook GS, Millward M, Hong D, Naing A, Piha-Paul S, Waguespack SG, Cabanillas ME, Sherman SI, Ma B, Curtis M, Goodman V, Kurzrock R. BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer. Thyroid 25(1):71-7, 2015. e-Pub 2015. PMID: 25285888.
Dadu R, Shah K, Busaidy NL, Waguespack SG, Habra MA, Ying AK, Hu MI, Bassett R, Jimenez C, Sherman SI, Cabanillas ME. Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience. J Clin Endocrinol Metab 100(1):E77-81, 2015. e-Pub 2015. PMID: 25353071.
Tuttle RM, Haddad RI, Ball DW, Byrd D, Dickson P, Duh QY, Ehya H, Haymart M, Hoh C, Hunt JP, Iagaru A, Kandeel F, Kopp P, Lamonica DM, Lydiatt WM, McCaffrey J, Moley JF, Parks L, Raeburn CD, Ridge JA, Ringel MD, Scheri RP, Shah JP, Sherman SI, Sturgeon C, Waguespack SG, Wang TN, Wirth LJ, Hoffmann KG, Hughes M. Thyroid carcinoma, version 2.2014. J Natl Compr Canc Netw 12(12):1671-80, 2014. e-Pub 2014. PMID: 25505208.
group member) CGARN(S. Integrated genomic characterization of papillary thyroid carcinoma. Cell 159(3):676-90, 2014. e-Pub 2014. PMID: 25417114.
Cabanillas ME, Brose MS, Holland J, Ferguson KC, Sherman SI. A phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer. Thyroid 24(10):1508-14, 2014. e-Pub 2014. PMID: 25102375.
Rich TA, Feng L, Busaidy N, Cote GJ, Gagel RF, Hu M, Jimenez C, Lee JE, Perrier N, Sherman SI, Waguespack SG, Ying A, Grubbs E. Prevalence by age and predictors of medullary thyroid cancer in patients with lower risk germline RET proto-oncogene mutations. Thyroid 24(7):1096-1106, 2014. e-Pub 2014. PMID: 24617864.
Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, de la Fouchardiere C, Pacini F, Paschke R, Shong YK, Sherman SI, Smit JW, Chung J, Kappeler C, Peña C, Molnár I, Schlumberger MJ, investigators D. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 384(9940):319-28, 2014. e-Pub 2014. PMID: 24768112.
Dadu R, Devine C, Hernandez M, Waguespack SG, Busaidy NL, Hu MI, Jimenez C, Habra MA, Sellin RV, Ying AK, Cote GJ, Sherman SI, Cabanillas ME. Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib. J Clin Endocrinol Metab 99(6):2086-94, 2014. e-Pub 2014. PMID: 24628550.
Dadu R, Waguespack SG, Sherman SI, Hu MI, Busaidy NL, Jimenez C, Habra MA, Ying AK, Bassett RL, Cabanillas ME. Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancer. Oncologist 19(5):477-82, 2014. e-Pub 2014. PMID: 24733667.
McLeod DS, Cooper DS, Ladenson PW, Ain KB, Brierley JD, Fein HG, Haugen BR, Jonklaas J, Magner J, Ross DS, Skarulis MC, Steward DL, Maxon HR, Study Group SSFTNTCTC. Prognosis of differentiated thyroid cancer in relation to serum TSH and thyroglobulin antibody status at time of diagnosis. Thyroid 24(1):35-42, 2014. e-Pub 2014. PMID: 23731273.
Kim KB, Cabanillas ME, Lazar AJ, Williams MD, Sanders DL, Ilagan JL, Nolop K, Lee RJ, Sherman SI. Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring V600E BRAF mutation. Thyroid 23(10):1277-83, 2013. e-Pub 2013. PMID: 23489023.
Elisei R, Schlumberger MJ, Müller SP, Schöffski P, Brose MS, Shah MH, Licitra L, Jarzab B, Medvedev V, Kreissl MC, Niederle B, Cohen EE, Wirth LJ, Ali H, Hessel C, Yaron Y, Ball D, Nelkin B, Sherman SI. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 31(29):3639-46, 2013. e-Pub 2013. PMID: 24002501.
Kurzrock R, Wheler AJ, Fu S, Naing A, Busaidy N, Hong D, Sherman S. Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy. Ann Oncol 24(9):2256-61, 2013. e-Pub 2013. PMID: 23676418.
Carhill AA, Cabanillas ME, Jimenez C, Waguespack SG, Habra MA, Hu M, Ying A, Vassilopoulou-Sellin R, Gagel RF, Sherman SI, Busaidy NL. The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring. J Clin Endocrinol Metab 98(1):31-42, 2013. e-Pub 2013. PMID: 23185034.
Jonklaas J, Nogueras-Gonzalez G, Munsell M, Litofsky D, Ain KB, Bigos ST, Brierley JD, Cooper DS, Haugen BR, Ladenson PW, Magner J, Robbins J, Ross DS, Skarulis MC, Steward DL, Maxon HR, Sherman SI, Study Group NTCTC. The impact of age and gender on papillary thyroid cancer survival. J Clin Endocrinol Metab 97(6):E878-87, 2012. e-Pub 2012. PMID: 22496497.
Moreno MA, Edeiken-Monroe BS, Siegel ER, Sherman SI, Clayman GL. In papillary thyroid cancer, preoperative central neck Ultrasound detects only macroscopic surgical disease, but negative findings predict excellent long-term regional control and survival. Thyroid 22(4):347-55, 2012. e-Pub 2012. PMID: 22280230.
Clayman GL, Agarwal G, Edeiken BS, Waguespack SG, Roberts DB, Sherman SI. Long-term outcome of comprehensive central compartment dissection in patients with recurrent/persistent papillary thyroid carcinoma. Thyroid 21(12):1309-16, 2011. e-Pub 2011. PMID: 22136266.
Chintharlapalli S, Papineni S, Lee SO, Lei P, Jin UH, Sherman SI, Santarpia L, Safe S. Inhibition of pituitary tumor-transforming gene-1 in thyroid cancer cells by drugs that decrease specificity proteins. Mol Carcinog 50(9):655-67, 2011. e-Pub 2011. PMID: 21268135.
Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, Pfister DG, Cohen EE, Janisch L, Nauling F, Hong DS, Ng CS, Ye L, Gagel RF, Frye J, Müller T, Ratain MJ, Salgia R. Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol 29(19):2660-6, 2011. e-Pub 2011. PMID: 21606412.
Hong DS, Cabanillas ME, Wheler J, Naing A, Tsimberidou AM, Ye L, Waguespack SG, Hernandez M, El Naggar AK, El Naggar AK, Bidyasar S, Wright J, Sherman SI, Kurzrock R, Busaidy NL. Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies. J Clin Endocrinol Metab 96(4):997-1005, 2011. e-Pub 2011. PMID: 21289252.
Moreno MA, Agarwal G, de Luna R, Siegel ER, Sherman SI, Edeiken-Monroe BS, Clayman GL. Preoperative lateral neck ultrasonography as a long-term outcome predictor in papillary thyroid cancer. Arch Otolaryngol Head Neck Surg 137(2):157-62, 2011. e-Pub 2011. PMID: 21339402.
Brose MS, Nutting CM, Sherman SI, Shong YK, Smit JW, Reike G, Chung J, Kalmus J, Kappeler C, Schlumberger M. Rationale and design of DECISION: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)–refractory, differentiated thyroid cancer. BMC Cancer 11(1):349, 2011. e-Pub 2011. PMID: 21834960.
Bass MB, Sherman SI, Schlumberger MJ, Davis MT, Kivman L, Khoo HM, Notari KH, Peach M, Hei YJ, Patterson SD. Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer. J Clin Endocrinol Metab 95(11):5018-27, 2010. e-Pub 2010. PMID: 20739388.
Tuttle RM, Ball DW, Byrd D, Dilawari RA, Doherty GM, Duh QY, Ehya H, Farrar WB, Haddad RI, Kandeel F, Kloos RT, Kopp P, Lamonica DM, Loree TR, Lydiatt WM, McCaffrey JC, Olson JA, Parks L, Ridge JA, Shah JP, Sherman SI, Sturgeon C, Waguespack SG, Wang TN, Wirth LJ. Thyroid carcinoma. J Natl Compr Canc Netw 8(11):1228-74, 2010. e-Pub 2010. PMID: 21081783.
Bhatia A, Rao A, Ang KK, Garden AS, Morrison WH, Rosenthal DI, Evans DB, Clayman G, Sherman SI, Schwartz DL. Anaplastic thyroid cancer: Clinical outcomes with conformal radiotherapy. Head Neck 32(7):829-36, 2010. e-Pub 2010. PMID: 19885924.
Cabanillas ME, Waguespack SG, Bronstein Y, Williams MD, Feng L, Hernandez M, Lopez A, Sherman SI, Busaidy NL. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience. J Clin Endocrinol Metab 95(6):2588-95, 2010. e-Pub 2010. PMID: 20392874.
Santarpia L, Myers JN, Sherman SI, Trimarchi F, Clayman GL, El-Naggar AK. Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma. Cancer 116(12):2974-83, 2010. e-Pub 2010. PMID: 20564403.
Tuttle RM, Ball DW, Byrd D, Daniels GH, Dilawari RA, Doherty GM, Duh QY, Ehya H, Farrar WB, Haddad RI, Kandeel F, Kloos RT, Kopp P, Lamonica DM, Loree TR, Lydiatt WM, McCaffrey J, Olson JA, Parks L, Ridge JA, Shah JP, Sherman SI, Sturgeon C, Waguespack SG, Wang TN, Wirth LJ, Cancer Network NC. Medullary carcinoma. J Natl Compr Canc Netw 8(5):512-30, 2010. e-Pub 2010. PMID: 20495082.
Drucker DJ, Sherman SI, Gorelick FS, Bergenstal RM, Sherwin RS, Buse JB. Incretin-based therapies for the treatment of type 2 diabetes; evaluation of the risks and benefits. Diabetes Care 33(2):428-433, 2010. e-Pub 2010. PMID: 20103558.
Hong DS, Sebti SM, Newman RA, Blaskovich MA, Ye L, Gagel RF, Moulder S, Wheler JJ, Naing A, Tannir NM, Ng CS, Sherman SI, El Naggar AK, Khan R, Trent J, Wright JJ, Kurzrock R. Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies. Clin Cancer Res 15(22):7061-8, 2009. e-Pub 2009. PMID: 19903778.
Elisei R, Schlumberger M, Driedger A, Reiners C, Kloos RT, Sherman SI, Haugen B, Corone C, Molinaro E, Grasso L, Leboulleux S, Rachinsky I, Luster M, Lassmann M, Busaidy NL, Wahl RL, Pacini F, Cho SY, Magner J, Pinchera A, Ladenson PW. Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants either after recombinant human thyrotropin or thyroid hormone withdrawal. J Clin Endocrinol Metab 94(11):4171-9, 2009. e-Pub 2009. PMID: 19850694.
Tsimberidou AM, Vaklavas C, Wen S, Hong D, Wheler J, Ng C, Naing A, Tse S, Busaidy N, Markman M, Sherman SI, Kurzrock R. Phase I clinical trials in 56 patients with thyroid cancer: The M. D. Anderson Cancer Center experience. J Clin Endocrinol Metab 94(11):4423-32, 2009. e-Pub 2009. PMID: 19820016.
Thyroid Nodules ATA(GTO, Cancer DT, Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19(11):1167-214, 2009. e-Pub 2009. PMID: 19860577.
Ross DS, Litofsky D, Ain KB, Bigos T, Brierley JD, Cooper DS, Haugen BR, Jonklaas J, Ladenson PW, Magner J, Robbins J, Skarulis MC, Steward DL, Maxon HR, Sherman SI. Recurrence after treatment of micropapillary thyroid cancer. Thyroid 19(10):1043-1048, 2009. e-Pub 2009. PMID: 19772419.
Clayman GL, Shellenberger TD, Ginsberg LE, Edeiken BS, El-Naggar AK, Sellin RV, Waguespack SG, Roberts DB, Mishra A, Sherman SI. Approach and safety of comprehensive central compartment dissection in patients with recurrent papillary thyroid carcinoma. Head Neck 31(9):1152-63, 2009. e-Pub 2009. PMID: 19360746.
Schlumberger MJ, Elisei R, Bastholt L, Wirth LJ, Martins RG, Locati LD, Jarzab B, Pacini F, Daumerie C, Droz JP, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Sherman SI. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 27(23):3794-801, 2009. e-Pub 2009. PMID: 19564535.
Smith GL, Smith BD, Garden AS, Rosenthal DI, Sherman SI, Morrison WH, Schwartz DL, Weber RS, Buchholz TA. Hypothyroidism in older patients with head and neck cancer after treatment with radiation: a population-based study. Head Neck 31(8):1031-8, 2009. e-Pub 2009. PMID: 19360741.
Schwartz DL, Lobo MJ, Ang KK, Morrison WH, Rosenthal DI, Ahamad A, Evans DB, Clayman G, Sherman SI, Garden AS. Post-operative external beam radiotherapy for differentiated thyroid cancer - Outcomes and morbidity with conformal treatment. Int J Radiat Oncol Biol Phys 74(4):1083-91, 2009. e-Pub 2009. PMID: 19095376.
Santarpia L, Sherman SI, Marabotti A, Clayman GL, El-Naggar AK. Detection and molecular characterization of a novel BRAF activated domain mutation in follicular variant of papillary thyroid carcinoma. Hum Pathol 40(6):827-33, 2009. e-Pub 2009. PMID: 19200582.
Hassan MM, Kaseb A, Li D, Patt YZ, Vauthey JN, Thomas MB, Curley SA, Spitz MR, Sherman SI, Abdalla EK, Davila M, Lozano RD, Hassan DM, Chan W, Brown TD, Abbruzzese JL. Association between hypothyroidism and hepatocellular carcinoma: USA case-control study. Hepatology 49(5):1563-70, 2009. e-Pub 2009. PMID: 19399911.
Leboulleux S, Schroeder PR, Busaidy NL, Auperin A, Corone C, Jacene HA, Ewertz ME, Bournaud C, Wahl RL, Sherman SI, Ladenson PW, Schlumberger M. Assessment of the incremental value of recombinant thyrotropin stimulation before 2-[18F]-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging to localize residual differentiated thyroid cancer. J Clin Endocrinol Metab 94(4):1310-6, 2009. e-Pub 2009. PMID: 19158200.
Waguespack SG, Sherman SI, Williams MD, Clayman GL, Herzog CE. The successful use of sorafenib to treat pediatric papillary thyroid carcinoma. Thyroid 19(4):407-12, 2009. e-Pub 2009. PMID: 19355831.
Santarpia L, Gagel RF, Sherman SI, Sarlis NJ, Evans DB, Hoff AO. Diabetes insipidus and panhypopituitarism due to intrasellar metastasis from medullary thyroid cancer. Head Neck 31(3):419-23, 2009. e-Pub 2009. PMID: 18798312.
Gning I, Trask PC, Mendoza TR, Harle MT, Gutierrez KA, Kitaka SA, Sherman SI, Cleeland CS. Development and initial validation of the thyroid cancer module of the M. D. Anderson Symptom Inventory (MDASI THY). Oncology 76(1):59-68, 2009. e-Pub 2009. PMID: 19052478.
Santarpia L, El-Naggar AK, Sherman SI, Hymes SR, Gagel RF, Shaw S, Sarlis NJ. Four patients with cutaneous metastases from medullary thyroid cancer. Thyroid 18(8):901-5, 2008. e-Pub 2008. PMID: 18651821.
Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, Licitra L, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Schlumberger MJ, Schlumberger MJ. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 359(1):31-42, 2008. e-Pub 2008. PMID: 18596272.
Schwartz DL, Rana V, Shaw S, Yazbeck C, Ang KK, Morrison WH, Rosenthal DI, Hoff A, Evans DB, Clayman GL, Garden AS, Sherman SI. Postoperative radiotherapy for advanced medullary thyroid cancer-Local disease control in the modern era. Head Neck 30(7):883-888, 2008. e-Pub 2008. PMID: 18213725.
Elliott DD, Sherman SI, Busaidy NL, Williams MD, Santarpia L, Clayman GL, El-Naggar AK. Growth factor receptors expression in anaplastic thyroid carcinoma: potential markers for therapeutic stratification. Hum Pathol 39(1):15-20, 2008. e-Pub 2008. PMID: 17949783.
Santarpia L, El-Naggar AK, Cote GJ, Myers JN, Sherman SI. Phosphatidylinositol 3-kinase/AKT and RAS/RAF-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer. J Clin Endocrinol Metab 93(1):278-84, 2008. e-Pub 2008. PMID: 17989125.
Santarpia L, Sarlis NJ, Santarpia M, Sherman SI, Trimarchi F, Benvenga S. Mosaicism in von Hippel-Lindau disease: an event important to recognize. J Cell Mol Med 11(6):1408-15, 2007. e-Pub 2007. PMID: 18205710.
Sherman SI. Practice point commentary: Can serum thyroglobulin levels predict patient outcome after treatment of differentiated thyroid carcinoma?. Nat Clin Pract Endocrinol Metab 3(7):510-511, 2007. e-Pub 2007. PMID: 17519916.
Sherman SI, Angelos P, Ball DW, Byrd D, Clark OH, Daniels GH, Dilawari RA, Ehya H, Farrar WB, Gagel RF, Kandeel F, Kloos RT, Kopp P, Lamonica DM, Loree TR, Lydiatt WM, McCaffrey J, Jr OJ, Ridge JA, Shah JP, Sisson JC, Tuttle RM, Urist MM, Carcinoma Panel NCCNT. Thyroid carcinoma. J Natl Compr Canc Netw 5(6):568-621, 2007. e-Pub 2007. PMID: 17623612.
|Sherman, SI. Can serum thyroglobulin levels predict patient outcome after treatment of differentiated thyroid carcinoma?. Nat Clin Pract Endocrinol Metab 3(7):510-511, 2007. e-Pub 2007. PMID: 17519916.
Golden WM, Weber KB, Hernandez TL, Sherman SI, Woodmansee WW, Haugen BR. Single-dose rexinoid rapidly and specifically suppresses serum thyrotropin in normal subjects. J Clin Endocrinol Metab 92(1):124-30, 2007. e-Pub 2007. PMID: 17062760.
Frates MC, Benson CB, Charboneau JW, Cibas ES, Clark OH, Coleman BG, Cronan JJ, Doubilet PM, Evans DB, Goellner JR, Hay ID, Hertzberg BS, Intenzo CM, Jeffrey RB, Langer JE, Larsen PR, Mandel SJ, Middleton WD, Reading CC, Sherman SI, Tessler FN, Tessler FN. Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statement. Ultrasound Q 22(3):231-8; discussion 239-40, 2006. e-Pub 2006. PMID: 17146329.
Jonklaas J, Sarlis NJ, Litofsky D, Ain KB, Bigos ST, Brierley JD, Cooper DS, Haugen BR, Ladenson PW, Magner J, Robbins J, Ross DS, Skarulis M, Maxon HR, Sherman SI. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 16(12):1229-42, 2006. e-Pub 2006. PMID: 17199433.
Mrozek E, Kloos RT, Ringel MD, Kresty L, Snider P, Arbogast D, Kies M, Munden R, Busaidy N, Klein MJ, Sherman SI, Shah MH. Phase II study of celecoxib in metastatic differentiated thyroid carcinoma. J Clin Endocrinol Metab 91(6):2201-2204, 2006. e-Pub 2006. PMID: 16522694.
Ghori F, Polder KD, Pinter-Brown LC, Hoff AO, Gagel RF, Sherman SI, Duvic M. Thyrotoxicosis after denileukin diftitox therapy in patients with mycosis fungoides. J Clin Endocrinol Metab 91(6):2205-8, 2006. e-Pub 2006. PMID: 16595600.
Hänscheid H, Lassmann M, Luster M, Thomas SR, Pacini F, Ceccarelli C, Ladenson PW, Wahl RL, Schlumberger M, Ricard M, Driedger A, Kloos RT, Sherman SI, Haugen BR, Carriere V, Corone C, Reiners C. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med 47(4):648-54, 2006. e-Pub 2006. PMID: 16595499.
Schroeder PR, Haugen BR, Pacini F, Reiners C, Schlumberger M, Sherman SI, Cooper DS, Schuff KG, Braverman LE, Skarulis MC, Davies TF, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Samuels MH, Weintraub BD, Ridgway EC, Ladenson PW. A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. J Clin Endocrinol Metab 91(3):878-84, 2006. e-Pub 2006. PMID: 16394083.
Pacini F, Ladenson PW, Schlumberger M, Driedger A, Luster M, Kloos RT, Sherman SI, Haugen B, Corone C, Molinaro E, Elisei R, Ceccarelli C, Pinchera A, Wahl RL, Leboulleux S, Ricard M, Yoo J, Busaidy NL, Delpassand E, Hanscheid H, Felbinger R, Lassmann M, Reiners C. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: Results of an international, randomized controlled study. J Clin Endocrinol Metab 91(3):926-932, 2006. e-Pub 2006. PMID: 16384850.
Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Sherman SI, Tuttle RM, Guidelines Taskforce ATA. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16(2):109-42, 2006. e-Pub 2006. PMID: 16420177.
Frates MC, Benson CB, Charboneau JW, Cibas ES, Clark OH, Coleman BG, Cronan JJ, Doubilet PM, Evans DB, Goellner JR, Hay ID, Hertzberg BS, Intenzo CM, Jeffrey RB, Langer JE, Larsen PR, Mandel SJ, Middleton WD, Reading CC, Sherman SI, Tessler FN, Tessler FN. Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statement. Radiology 237(3):794-800, 2005. e-Pub 2005. PMID: 16304103.
Sherman SI, Angelos P, Ball DW, Beenken SW, Byrd D, Clark OH, Daniels GH, Dilawari RA, Ehya H, Farrar WB, Gagel RF, Kandeel F, Kloos RT, Kopp P, Lamonica DM, Loree TR, Lydiatt WM, McCaffrey J, Olson JA, Jr, Ridge JA, Robbins R, Shah JP, Sisson JC, Thompson NW. Thyroid carcinoma. J Natl Compr Canc Netw 3(3):404-57, 2005. e-Pub 2005. PMID: 16002006.
Schiff BA, McMurphy AB, Jasser SA, Younes MN, Doan D, Yigitbasi OG, Kim S, Zhou G, Mandal M, Bekele BN, Holsinger FC, Sherman SI, Yeung SC, El-Naggar AK, Myers JN. Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer. Clin Cancer Res 10(24):8594-602, 2004. e-Pub 2004. PMID: 15623643.
Kouvaraki MA, Lee JE, Shapiro SE, Sherman SI, Evans DB. Preventable reoperations for persistent and recurrent papillary thyroid carcinoma. Surgery 136(6):1183-91, 2004. e-Pub 2004. PMID: 15657574.
Busaidy NL, Jimenez C, Habra MA, Schultz PN, El-Naggar AK, Clayman GL, Asper JA, Diaz EM, Evans DB, Gagel RF, Garden A, Hoff AO, Lee JE, Morrison WH, Rosenthal DI, Sherman SI, Sturgis EM, Waguespack SG, Weber RS, Wirfel K, Vassilopoulou-Sellin R. Parathyroid carcinoma: a 22-year experience. Head Neck 26(8):716-26, 2004. e-Pub 2004. PMID: 15287039.
Yip L, Lee JE, Shapiro SE, Waguespack SG, Sherman SI, Hoff AO, Gagel RF, Arens JF, Evans DB. Surgical management of hereditary pheochromocytoma. J Am Coll Surg 198(4):525-34; discussion 534-5, 2004. e-Pub 2004. PMID: 15051000.
Kouvaraki MA, Shapiro SE, Fornage BD, Edeiken-Monroe BS, Sherman SI, Vassilopoulou-Sellin R, Lee JE, Evans DB. Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. Surgery 134(6):946-54; discussion 954-5, 2003. e-Pub 2003. PMID: 14668727.
Sclabas GM, Staerkel GA, Shapiro SE, Fornage BD, Sherman SI, Vassilopoulou-Sellin R, Lee JE, Evans DB. Fine-needle aspiration of the thyroid and correlation with histopathology in a contemporary series of 240 patients. Am J Surg 186(6):702-9; discussion 709-10, 2003. e-Pub 2003. PMID: 14672783.
Pederson LC, Shapiro SE, Fritsche HA, Delpassand ES, Gagel RF, Sherman SI, Vassilopoulou-Sellin R, Evans DB, Lee JE. Potential role for intraoperative gamma probe identification of normal parathyroid glands. Am J Surg 186(6):711-7, 2003. e-Pub 2003. PMID: 14672784.
Yen TW, Shapiro SE, Gagel RF, Sherman SI, Lee JE, Evans DB. Medullary thyroid carcinoma: results of a standardized surgical approach in a contemporary series of 80 consecutive patients. Surgery 134(6):890-9; discussion 899-901, 2003. e-Pub 2003. PMID: 14668720.
Shepler TR, Sherman SI, Faustina MM, Busaidy NL, Ahmadi MA, Esmaeli B. Nasolacrimal duct obstruction associated with radioactive iodine therapy for thyroid carcinoma. Ophthal Plast Reconstr Surg 19(6):479-81, 2003. e-Pub 2003. PMID: 14625496.
Luster M, Sherman SI, Skarulis MC, Reynolds JR, Lassmann M, Hänscheid H, Reiners C. Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma. Eur J Nucl Med Mol Imaging 30(10):1371-7, 2003. e-Pub 2003. PMID: 12856155.
Yip L, Cote GJ, Shapiro SE, Ayers GD, Herzog CE, Sellin RV, Sherman SI, Gagel RF, Lee JE, Evans DB. Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship. Arch Surg 138(4):409-16; discussion 416, 2003. e-Pub 2003. PMID: 12686527.
Lopez-Penabad L, Chiu AC, Hoff AO, Schultz P, Gaztambide S, Ordoñez NG, Sherman SI. Prognostic factors in patients with Hurthle cell neoplasms of the thyroid. Cancer 97(5):1186-94, 2003. e-Pub 2003. PMID: 12599224.
Sherman, SI. Thyroid Carcinoma. Lancet 361(9356):501-511, 2003. e-Pub 2003. PMID: 12583960.
Royal RE, Delpassand ES, Shapiro SE, Fritsche HA, Vassilopoulou-Sellin R, Sherman SI, Gagel RF, Evans DB, Lee JE. Improving the yield of preoperative parathyroid localization: technetium Tc 99m-sestamibi imaging after thyroid suppression. Surgery 132(6):968-74; discussion 974-5, 2002. e-Pub 2002. PMID: 12490843.
Ghori FY, Gutterman-Litofsky DR, Jamal A, Yeung SC, Arem R, Sherman SI. Socioeconomic factors and the presentation, management, and outcome of patients with differentiated thyroid carcinoma. Thyroid 12(11):1009-16, 2002. e-Pub 2002. PMID: 12490079.
Kouvaraki MA, Lee JE, Shapiro SE, Gagel RF, Sherman SI, Sellin RV, Cote GJ, Evans DB. Genotype-phenotype analysis in multiple endocrine neoplasia type 1. Arch Surg 137(6):641-7, 2002. e-Pub 2002. PMID: 12049533.
Wartofsky L, (group member) SS. Management of low risk well differentiated thyroid cancer based only on thyroglobulin measurement after recombinant human thyrotropin. the rhTSH-Stimulated Thyroglobulin Study Group. Thyroid 12(7):583-590, 2002. e-Pub 2002. PMID: 12193302.
Esnaola NF, Cantor SB, Sherman SI, Lee JE, Evans DB. Optimal treatment strategy in patients with papillary thyroid cancer: A decision analysis. Surgery 130(6):921-30, 2001. e-Pub 2001. PMID: 11742318.
Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI, Cooper DS, Graham KE, Braverman LE, Skarulis MC, Davies TF, DeGroot LJ, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Samuels MH, Becker DV, Maxon HR, Cavalieri RR, Spencer CA, McEllin K, Weintraub BD, Ridgway EC. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 84(11):3877-85, 1999. e-Pub 1999. PMID: 10566623.
Sturgis CD, Caraway NP, Johnston DA, Sherman SI, Kidd L, Katz RL. Image analysis of papillary thyroid carcinoma fine-needle aspirates: significant association between aneuploidy and death from disease. Cancer 87(3):155-60, 1999. e-Pub 1999. PMID: 10385447.
Arem R, Padayatty SJ, Saliby AH, Sherman SI. Thyroid microcarcinoma: prevalence, prognosis, and management. Endocr Pract 5(3):148-56, 1999. e-Pub 1999. PMID: 15251688.
Sherman SI, Gopal J, Haugen BR, Chiu AC, Whaley K, Nowlakha P, Duvic M. Central hypothyroidism associated with retinoid X receptor-selective ligands. N Engl J Med 340(14):1075-9, 1999. e-Pub 1999. PMID: 10194237.
Taylor T, Specker B, Robbins J, Sperling M, Ho M, Ain K, Bigos ST, Brierley J, Cooper D, Haugen B, Hay I, Hertzberg V, Klein I, Klein H, Ladenson P, Nishiyama R, Ross D, Sherman S, Maxon HR. Outcome after treatment of high-risk papillary and non-Hürthle-cell follicular thyroid carcinoma. Ann Intern Med 129(8):622-7, 1998. e-Pub 1998. PMID: 9786809.
Sherman SI, Brierley JD, Sperling M, Ain KB, Bigos ST, Cooper DS, Haugen BR, Ho M, Klein I, Ladenson PW, Robbins J, Ross DS, Specker B, Taylor T, Maxon HR. Prospective multicenter study of thyroid carcinoma treatment: Initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. Cancer 83(5):1012-21, 1998. e-Pub 1998. PMID: 9731906.
Cooper DS, Specker B, Ho M, Sperling M, Ladenson PW, Ross DS, Ain KB, Bigos ST, Brierley JD, Haugen BR, Klein I, Robbins J, Sherman SI, Taylor T, Maxon HR. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid 8(9):737-44, 1998. e-Pub 1998. PMID: 9777742.
Chiu AC, Sherman SI. Effects of pharmacological fiber supplements on levothyroxine absorption. Thyroid 8(8):667-71, 1998. e-Pub 1998. PMID: 9737361.
Chiu AC, Delpassand ES, Sherman SI. Prognosis and treatment of brain metastases in thyroid carcinoma. J Clin Endocrinol Metab 82(11):3637-42, 1997. e-Pub 1997. PMID: 9360519.
Sherman SI, Ringel MD, Smith MJ, Kopelen HA, Zoghbi WA, Ladenson PW. Augmented hepatic and skeletal thyromimetic effects of tiratricol in comparison with levothyroxine. J Clin Endocrinol Metab 82(7):2153-8, 1997. e-Pub 1997. PMID: 9215287.
Sherman SI, Simonson L, Ladenson PW. Clinical and socioeconomic predispositions to complicated thyrotoxicosis: a predictable and preventable syndrome?. Am J Med 101(2):192-8, 1996. e-Pub 1996. PMID: 8757360.
Sherman SI, Malecha SE. Absorption and malabsorption of levothyroxine sodium. Am J Ther 2(10):814-818, 1995. e-Pub 1995. PMID: 11854792.
Sherman SI, Tielens ET, Ladenson PW. Sucralfate causes malabsorption of L-thyroxine. Am J Med 96(6):531-5, 1994. e-Pub 1994. PMID: 8017451.
Sherman SI, Tielens ET, Sostre S, Wharam MD, Ladenson PW. Clinical utility of post treatment radioiodine scans in the management of patients with thyroid carcinoma. J Clin Endocrinol Metab 78(3):629-34, 1994. e-Pub 1994. PMID: 8126134.
Tielens ET, Sherman SI, Hruban RH, Ladenson PW. Follicular variant of papillary thyroid carcinoma. A clinicopathologic study. Cancer 73(2):424-31, 1994. e-Pub 1994. PMID: 8293410.
Sherman SI, Ladenson PW. Organ-specific effects of tiratricol: a thyroid hormone analogue with hepatic, not pituitary, superagonist effects. J Clin Endocrinol Metab 75(3):901-5, 1992. e-Pub 1992. PMID: 1517383.
Ladenson PW, Sherman SI, Baughman KL, Ray PE, Feldman AM. Reversible alterations in myocardial gene expression in a young man with dilated cardiomyopathy and hypothyroidism. Proc Natl Acad Sci U S A 89(12):5251-5, 1992. e-Pub 1992. PMID: 1376915.
Sherman SI, Ladenson PW. Octreotide therapy of growth hormone excess in the McCune-Albright syndrome. J Endocrinol Invest 15(3):185-90, 1992. e-Pub 1992. PMID: 1624678.
Sherman SI, Ladenson PW. Percutaneous transluminal coronary angioplasty in hypothyroidism. Am J Med 90(3):367-70, 1991. e-Pub 1991. PMID: 2003519.

Invited Articles

Hofmann MC, Kunnimalaiyaan M, Wang JR, Busaidy NL, Sherman SI, Lai SY, Zafereo M, Cabanillas ME. Molecular mechanisms of resistance to kinase inhibitors in thyroid cancers. Endocr Relat Cancer 29(11):R173-R190, 2022. e-Pub 2022. PMID: 35975971.
Cabanillas ME, Busaidy NL, Sherman SI. Redifferentiation therapy-Returning to our roots in a post-kinase inhibitor world. Clin Cancer Res 28(19):4164-4166, 2022. e-Pub 2022. PMID: 35895318.
Weitzman SP, Sherman SI. Novel Drug Treatments of Progressive Radioiodine Refractory Differentiated Thyroid Cancer. Endocrinol Metab Clin North Am 48(1):253-268, 2019. e-Pub 2019. PMID: 30717907.
Sherman SI. Evolution of Targeted Therapies for Thyroid Carcinoma. Transactions of the American Clinical and Climatological Association 130:255-265, 2019. e-Pub 2019. PMID: 31516190.
Haugen BR, Sawka AM, Alexander EK, Bible KC, Caturegli P, Doherty GM, Mandel SJ, Morris JC, Nassar A, Pacini F, Schlumberger M, Schuff K, Sherman SI, Somerset H, Sosa JA, Steward DL, Wartofsky L, Williams MD. American Thyroid Association Guidelines on the Management of Thyroid Nodules and Differentiated Thyroid Cancer Task Force Review and Recommendation on the Proposed Renaming of Encapsulated Follicular Variant Papillary Thyroid Carcinoma Without Invasion to Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features. Thyroid 27(4):481-483, 2017. e-Pub 2017. PMID: 28114862.
Dralle H, Machens A, Basa J, Fatourechi V, Franceschi S, Hay ID, Nikiforov YE, Pacini F, Pasieka JL, Sherman SI. Follicular Cell-derived Thyroid Cancer. Nat Rev Dis Primers 1(Article number 15077):15077, 2015. e-Pub 2015. PMID: 27188261.
Sherman SI. Molecular mechanisms in thyroid cancer biology. Clinical Advances in Hematology and Oncology 12(7):10-13, 2014. e-Pub 2014.
Czerwonka L, Freeman J, McIver B, Randolph GW, Shah JP, Shaha AR, Sherman SI, Tuttle RM, Witterick IJ. Summary of proceedings of the second World Congress on Thyroid Cancer. Head and Neck 36(7):917-920, 2014. e-Pub 2014. PMID: 24677329.
Haddad R, Sherman SI, Shah JP, Wirth LJ. New frontiers and treatment paradigms for thyroid carcinoma. Clinical Advances in Hematology & Oncology 12(7):3-22, 2014. e-Pub 2014. PMID: 25768715.
Sherman SI. Overview of radioactive iodine-resistant differentiated thyroid cancer. Clinical Advances in Hematology and Oncology 12(7):3-5, 2014. e-Pub 2014.
Sherman SI. Lessons learned and questions unanswered from use of multitargeted kinase inhibitors in medullary thyroid cancer. Oral Oncol 49(7):707-10, 2013. e-Pub 2013. PMID: 23582411.
Haugen BR, Sherman SI. Evolving approaches to patients with advanced differentiated thyroid cancer. Endocr Rev 34(3):439-455, 2013. e-Pub 2013. PMID: 23575762.
Witt RL, Ferris RL, Pribitkin EA, Sherman SI, Steward DL, Nikiforov YE. Diagnosis and management of differentiated thyroid cancer using molecular biology. Laryngoscope 123(4):1059-64, 2013. e-Pub 2013. PMID: 23404751.
Sherman SI. The role of recombinant human thyrotropin for diagnostic monitoring of patients with differentiated thyroid cancer. Endocr Pract 19(1):157-61, 2013. e-Pub 2013. PMID: 23435044.
Cabanillas ME, Sherman SI. Applying new clinicopathologic characteristics to prognostication in advanced thyroid carcinoma. Endocr Relat Cancer 19(2):C19-22, 2012. e-Pub 2012. PMID: 22241721.
Schlumberger M, Sherman SI. Approach to the patient with advanced differentiated thyroid cancer. Eur J Endocrinol 166(1):5-11, 2012. e-Pub 2012. PMID: 21890651.
Drucker DJ, Sherman SI, Bergenstal RM, Buse JB. The safety of incretin-based therapies-review of the scientific evidence. J Clin Endocrinol Metab 96(7):2027-31, 2011. e-Pub 2011. PMID: 21734003.
Sherman SI. Targeted therapies for thyroid tumors. Mod Pathol 24 Suppl 2:S44-52, 2011. e-Pub 2011. PMID: 21455200.
Sherman SI. Targeted therapy of thyroid cancer. Biochem Pharmacol 80(5):592-601, 2010. e-Pub 2010. PMID: 20471374.
Sherman SI. Cytotoxic chemotherapy for differentiated thyroid carcinoma. Clin Oncol (R Coll Radiol) 22(6):464-8, 2010. e-Pub 2010. PMID: 20452757.
Sherman SI. Chemotherapy and immunotherapy for medullary thyroid carcinoma. UpToDate 18(2), 2010. e-Pub 2010.
Sherman SI. Chemotherapy for differentiated thyroid cancer. UpToDate 18(2), 2010. e-Pub 2010.
Sherman SI. Tyrosine kinase inhibitors and the thyroid. Best Pract Res Clin Endocrinol Metab 23(6):713-722, 2009. e-Pub 2009. PMID: 19942148.
Schlumberger M, Sherman SI. Clinical trials for progressive differentiated thyroid cancer: Patient selection, study design, and recent advances. Thyroid 19(12):1393-1400, 2009. e-Pub 2009. PMID: 20001721.
Sherman SI. Molecularly targeted therapies for thyroid cancers. Endocr Pract 15(6):1-27, 2009. e-Pub 2009. PMID: 19546052.
Sherman SI. Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers. J Clin Endocrinol Metab 94(5):1493-9, 2009. e-Pub 2009. PMID: 19258410.
Sherman SI. Early clinical studies of novel therapies for thyroid cancers. Endocrinol Metab Clin North Am 37(2):511-24, xi, 2008. e-Pub 2008. PMID: 18502340.
Sherman SI. New approaches to therapy of thyroid malignancies. Clin Adv Hematol Oncol 5(7):539-541, 2007. e-Pub 2007. PMID: 17679927.
Sherman SI. Cancer disparities and thyroid carcinoma. Curr Opin Endocrinol Metab 13:451-4, 2006. e-Pub 2006.
Sherman SI. Review of undifferentiated thyroglobulin-positive thyroid cancer 45 years after treatment for papillary primary. Clin Adv Hemat Oncol 1(4):243, 2005. e-Pub 2005.
Sherman SI. Commentary on: Angelos P. Current approaches to the treatment of well-differentiated thyroid cancer. Oncology (Huntington) 16(3):309-315, discussion 315, 318, 323-4,, 2002. e-Pub 2002.
Tyler DS, Shaha AR, Udelsman RA, Sherman SI, Thompson NW, Moley JF, Evans DB. Thyroid cancer: 1999 update. Ann Surg Oncol 7(5):376-98, 2000. e-Pub 2000. PMID: 10864346.
Sherman SI. The management of metastatic differentiated thyroid carcinoma. Rev Endocr Metab Disord 1(3)(3):165-71, 2000. e-Pub 2000. PMID: 11705002.
Sherman SI. Thyroid carcinoma. Lancet 361(9356):501-11, 2000. e-Pub 2000. PMID: 12583960.
Sherman SI. Clinicopathologic and prognostic staging for thyroid carcinomas. Thyroid Today 23(3):1-9, 2000. e-Pub 2000.
Sherman, SI, Gillenwater AM, Goepfert H. Advances in the management of cancer of the thyroid gland. Advances in Otolaryngology B Head and Neck Surgery 14:75-106, 2000. e-Pub 2000.
Sherman SI. Papillary thyroid carcinoma. UpToDate in Medicine [CD-ROM] 8(2, 2000. e-Pub 2000.
Sherman SI. Toward a standard clinicopathologic staging approach for differentiated thyroid carcinoma. Semin Surg Oncol 16(1):12-5, 1999. e-Pub 1999. PMID: 9890734.
Sherman SI. Adjuvant therapy and long-term management of differentiated thyroid carcinoma. Semin Surg Oncol 16(1):30-3, 1999. e-Pub 1999. PMID: 9890737.
Sherman SI. Serum thyroglobulin in the management of differentiated thyroid carcinoma. UpToDate in Medicine [CD-ROM] 6(3), 1998. e-Pub 1998.
Sherman SI. Clinicopathologic staging of differentiated thyroid carcinoma. UpToDate in Medicine [CD-ROM] 5(1), 1997. e-Pub 1997.
Sherman SI. Medullary thyroid carcinoma: Clinical presentation, genetics, and prognostic staging. UpToDate in Medicine [CD-ROM] 5(2), 1997. e-Pub 1997.
Sherman SI. Management of differentiated thyroid carcinoma. An overview. UpToDate in Medicine [CD-ROM] 5(1), 1997. e-Pub 1997.
Sherman SI. Anaplastic thyroid carcinoma. UpToDate in Medicine [CD-ROM] 5(2), 1997. e-Pub 1997.
Sherman SI. Medullary thyroid carcinoma: Treatment. . UpToDate in Medicine [CD-ROM] 5(2), 1997. e-Pub 1997.
Sherman SI. Surgery for differentiated thyroid carcinoma. UpToDate in Medicine [CD-ROM] 4(3), 1996. e-Pub 1996.
Sherman SI. Radioiodine treatment of differentiated thyroid cancer. UpToDate in Medicine [CD-ROM] 4(2), 1996. e-Pub 1996.
Evans, DB, Sherman SI. Long-term follow-up and management of papillary adenocarcinoma of the thyroid. Collected Letters in Surgery 18(9):5-7, 1995. e-Pub 1995.

Review Articles

Hamidi, S, Maniakas, A, Akhave, NS, Banuchi, VE, Busaidy, NL, Dadu, R, Ferrarotto, R, Guise, TA, Hofmann, M, Hosseini, SM, Hu, MI, Iyer, PC, Mansour, M, Marczyk, VR, Roy Chowdhuri, S, Sherman, SI, Sousa, LG, Wang, RJ, Williams, MD, Zafereo, M, Waguespack, SG, Cabanillas, ME. Characterization of Advanced RAS-driven Follicular-derived Thyroid Cancers and Review of Future Therapeutic Avenues. Journal of Clinical Endocrinology and Metabolism 111(2):471-483, 2026. e-Pub 2026. PMID: 40568752.
Kouvaraki MA, Shapiro SE, Perrier ND, Cote GJ, Gagel RF, Hoff AO, Sherman SI, Lee JE, Evans DB. RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid 15(6):531-44, 2005. e-Pub 2005. PMID: 16029119.
Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L, Haugen BR, Sherman SI, Cooper DS, Braunstein GD, Lee S, Davies TF, Arafah BM, Ladenson PW, Pinchera A. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 88(4):1433-41, 2003. e-Pub 2003. PMID: 12679418.
Sherman SI. Etiology, diagnosis, and treatment recommendations for central hypothyroidism associated with bexarotene therapy for cutaneous T-cell lymphoma. Clin Lymphoma 3(4):249-52, 2003. e-Pub 2003. PMID: 12672276.
McCutcheon IE, Kitagawa RH, Sherman SI, Bruner JM. Adenocarcinoma of the salivary gland metastatic to the pituitary gland: case report. Neurosurgery 48(5):1161-5; discussion 1165-6, 2001. e-Pub 2001. PMID: 11334286.
Fleming JB, Lee JE, Bouvet M, Schultz PN, Sherman SI, Sellin RV, Friend KE, Burgess MA, Cote GJ, Gagel RF, Evans DB. Surgical strategy for the treatment of medullary thyroid carcinoma. Ann Surg 230(5):697-707, 1999. e-Pub 1999. PMID: 10561095.
Wartofsky L, Sherman SI, Gopal J, Schlumberger M, Hay ID. The use of radioactive iodine in patients with papillary and follicular thyroid cancer. J Clin Endocrinol Metab 83(12):4195-203, 1998. e-Pub 1998. PMID: 9851751.
Lee JE, Evans DB, Hickey RC, Sherman SI, Gagel RF, Abbruzzese MC, Abbruzzese JL. Unknown primary cancer presenting as an adrenal mass: frequency and implications for diagnostic evaluation of adrenal incidentalomas. Surgery 124(6):1115-22, 1998. e-Pub 1998. PMID: 9854592.

Professional Educational Materials

Sherman SI, Haddad RI. Implementing the Updated American Thyroid Association Guidelines and Recommendations for RAI-R DTC. Medscape Education, 2015.
Sherman SI. Your Care Path: Thyroidectomy. Prepared for patients entered in institutional critical pathways for thyroid surgery, 2000.

Editorials

Sturgis EM, Sherman SI. Should papillary thyroid carcinoma be observed?: a word of caution. Arch Otolaryngol Head Neck Surg 136(5):444-6, 2010. PMID: 20479372.
Sherman SI, Fagin J. Why thyroid cancer?. Thyroid 15(4):303-04, 2005.
Sherman SI. Optimizing the outcomes of adjuvant radioiodine therapy in differentiated thyroid carcinoma. J Clin Endocrinol Metab 87(9):4059-4062, 2002. PMID: 12213844.
Sherman SI. Staging of thyroid carcinoma--reply. Cancer 83(5):848-50, 1998. PMID: 9731885.
Sherman SI. The risks of thyroidectomy: words of caution for referring physicians. J Gen Intern Med 13(1):60-1, 1998. PMID: 9462498.

Abstracts

Wirth, LJ, Brose, MS, Sherman, EJ, Misir, S, Xie, S, Almonte, A, Ye, W, Licitra, L, Schlumberger, M, Sherman, SI, Cabanillas, M. An Open-Label, Single-Arm, Multicenter, Phase 2 Trial of Lenvatinib (LEN) for the Treatment of Anaplastic Thyroid Cancer (ATC). Journal of the Endocrine Society 4(Supplement 1):MON-521, 2020. e-Pub 2020.
Fazeli, S, Dadu, R, Waguespack, SG, Sherman, SI, Busaidy, NL, Hu, MI, Jimenez, C, Habra, MA, Williams, M, Altameemi, L, Poropatich, K, Routbort, MJ, Luthra, R, Patel, KP, Cabanillas, M. TRK-Fusion Thyroid Cancer: A Clinical Overview in a Large Population at a Single Cancer Center. Journal of the Endocrine Society 4(Supplement 1):MON-491, 2020. e-Pub 2020.
Hurst ZA, Liyanarachchi S, He H, Brock P, Walker C, Sipos J, Nabhan F, Li W, Yilmaz S, Ozer G, Webb A, Gadepalli V, Chang Y, Xue S, Genutis L, Menq E, Green P, Kebebew E, Cote G, Sherman SI, de la Chapelle A, Jhiang SM. Germline SNPS Uniquely Associated with Radioiodine Refractory Thyroid Cancer Patients of High African Ancestry. American Thyroid Association, 2018. e-Pub 2018.
Brose MS, Robinson B, Capdevila J, Puvvada S, Wu W, Schlumberger M, Sherman SI. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib in Patients with Radioiodine (RAI)-Refractory Differentiated Thyroid Cancer (DTC) Who Have Progressed After Prior VEGFR-Targeted Therapy. American Thyroid Association, 2018. e-Pub 2018.
Dadu R, Cabanillas ME, de Groot P, Chang JY, Tang C, Sherman SI, Busaidy N, Waguespack SG, Hu M, Ying A, Habra M, Menon H, Welsh J. Ipilimumab with Stereotactic Ablative Radiation Therapy (SABR): Results of a Thyroid Cancer Expansion Cohort. American Thyroid Association, 2018. e-Pub 2018.
Xu JY, Handy BC, Waguespack SG, Hu MIN, Busaidy NL, Jimenez C, Cabanillas ME, Cote GJ, Sherman SI. Effect of circulating tumor cells (CTCs) on overall survival in metastatic medullary thyroid cancer (metMTC). Journal of Clinical Oncology 34(15), 2016. e-Pub 2016.
Xu JY, Zaidi TM, Cote GJ, Hu MIN, Waguespack SG, Cabanillas ME, Ying AK, Busaidy NL, Habra MA, Shanbhag N, Truong D, Yu RK, Shete S, Katz RL, Sherman SI. Accurate detection of circulating tumor cells (CTCs) in patients with metastatic papillary thyroid cancer (MPTC) via an interphase fluorescence in situ hybridization (IFISH) assay. Journal of Clinical Oncology 34(15), 2016. e-Pub 2016.
Khan SA, Ci B, Gerber DE, McFadden DG, Beg MS, Xie Y, Kurian P, Cabanillas ME, Busaidy NL, Sherman SI, Heilmann A, Ross JS, Bailey M, Burtness B, Ali SM. Comprehensive genomic sequencing (CGS) of 90 patient samples of anaplastic thyroid cancer (ATC). Journal of Clinical Oncology 34(15), 2016. e-Pub 2016.
Kwatampora L, Clarke C, Silva A, Zorba Y, Williams MD, Broaddus R, Clayman GL, El-Naggar AK, Gagel RF, Grubbs EG, Habra MA, Hu MIN, Jimenez C, Kopetz S, Lee JE, Sherman SI, Vassilopoulou-Sellin R, Waguespack S, Perrier ND, Busaidy NL. Recurrent parathyroid carcinoma and the need for molecular profiling to aid in prognostication and therapeutics. Journal of Clinical Oncology 33(15), 2015. e-Pub 2015.
Sherman SI, Pagan M, Huang J, Lin B, Diggans J, Tom E, Haugen B, Tuttle RM, Kennedy G. Augmenting pre-operative risk of recurrence stratification in differentiated thyroid carcinoma using machine learning and high dimensional transcriptional data from thyroid FNA. Journal of Clinical Oncology 33(15), 2015. e-Pub 2015.
Brose MS, Schlumberger M, Tahara M, Wirth LJ, Robinson B, Elisei R, Newbold K, Kiyota N, Hoff AO, Dutcus C, Song J, Sherman SI, Taylor MH. Effect of age and lenvatinib treatment on overall survival for patients with I-131-refractory differentiated thyroid cancer in SELECT. Journal of Clinical Oncology 33(15), 2015. e-Pub 2015.
Schlumberger M, Elisei R, Muller S, Schoffski P, Brose MS, Shah MH, Licitra LF, Jarzab B, Medvedev V, Kreissl M, Cohen EEW, Wirth LJ, Ali HY, Hessel C, Yaron Y, Ball DW, Nelkin B, Sherman SI. Final overall survival analysis of EXAM, an international, double-blind, randomized, placebo-controlled phase III trial of cabozantinib (Cabo) in medullary thyroid carcinoma (MTC) patients with documented RECIST progression at baseline. Journal of Clinical Oncology 33(15), 2015. e-Pub 2015.
Tahara M, Schlumberger M, Elisei R, Habra MA, Kiyota N, Dutcus C, Xu JB, Zhu JM, Hihara T, McGrath S, Matijevic M, Kadowaki T, Funahashi Y, Sherman SI. Pharmacodynamic biomarkers of outcomes in the phase III study of lenvatinib in I-131-refractory differentiated thyroid cancer (SELECT). Journal of Clinical Oncology 33(15), 2015. e-Pub 2015.
Worden FP, Fassnacht M, Shi YK, Hadjieva T, Bonichon F, Gao M, Fugazzola L, Ando Y, Hasegawa Y, Park DJ, Nutting C, Sherman SI, Shong YK, Smit JWA, Chung JW, Kappeler C, Molnar I, Schlumberger M, Brose MS. Safety and tolerability of sorafenib for treatment of locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC): Detailed analyses from the phase III DECISION trial. Journal of Clinical Oncology 32(15), 2014. e-Pub 2014.
Brose MS, Jarzab B, Elisei R, Siena S, Bastholt L, De La Fouchardiere C, Pacini F, Paschke R, Nutting C, Shong YK, Sherman SI, Smit JWA, Chung JW, Kappeler C, Molnar I, Schlumberger M. Updated overall survival analysis of patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) treated with sorafenib on the phase 3 DECISION trial. Journal of Clinical Oncology 32(15), 2014. e-Pub 2014.
Bupathi M, Falchook GS, Hong DS, Subbiah IM, Piha-Paul SA, Karp DD, Salgal B, Zinner R, Wheler JJ, Tsimberidou AM, Fu SQ, Sherman SI, Meric-Bernstam F, Subbiah V. A phase 1 trial of vandetanib (multikinase inhibitor of EGFR, VEGFR, and RET) in combination with everolimus (mTOR inhibitor) in patients with advanced malignancies. Journal of Clinical Oncology 32(15), 2014. e-Pub 2014.
Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Ellsel R, Dutcus CE, de las Hares B, Zhu JM, Habra MA, Newbold K, Shah MH, Hoff AO, Gianoukakis AG, Kiyota N, Taylor MH, Kim SB, Krzyranowska MK, Sherman SI. A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with I-134-refractory differentiated thyroid cancer (SELECT). Journal of Clinical Oncology 32(15), 2014. e-Pub 2014.
Sherman SI, Cohen EW, Schoffski P, Elisei R, Schlumberger M, Wirth LJ, Mangeshkar M, Aftab DT, Clary DO, Brose MS. Efficacy of cabozantinib (Cabo) in medullary thyroid cancer (MTC) patients with RAS or RET mutations: Results from a phase III study. Amer Soc Clin Oncol (ASCO), 2013. e-Pub 2013.
Sherman SI, Michaelis C, Gornet T, Handy B, Waguespack SG, Hu MI, Busaidy NL, Jimenez C, Cabanillas ME, Cote G. Overall survival is reduced in patients with detectable circulating tumor cells from metastatic medullary thyroid cancer. Amer Thyroid Assoc, 2013. e-Pub 2013.
Cabanillas ME, Holsinger FC, Sturgis EM, Habra MA, Davies MA, Munsell MF, French J, Busaidy N, Hu MI, Sherman SI. Pharmacodynamic study of neoadjuvant vemurafenib (VEM) in patients (pts) with BRAF mutated, locally advanced papillary thyroid cancer (PTC). Amer Soc Clin Oncol (ASCO), 2013. e-Pub 2013.
Sherman SI. Emerging treatments in thyroid cancer. Clinical Advances in Hematology and Oncology 10(9):594-595, 2012. e-Pub 2012. PMID: 23073125.
Ahmed SR, Azad NS, Ball DW, Rudek MA, Nelkin B, Cosgrove D, Gong J, Finkelstein D, Zahurak M, Janku F, Downs M, O'Connor A, Markus S, Carducci MA, Sherman SI, Kurzrock R. A phase I study determining the safety and tolerability of combination therapy with pazopanib, a VEGFR/PDGFR/raf inhibitor, and GSK1120212, a MEK inhibitor, in advanced solid tumors enriched with patients with advanced differentiated thyroid cancer. Amer Soc Clin Oncol (ASCO), 2012. e-Pub 2012.
Cabanillas ME, Brose MS, Ramies DA, Lee Y, Miles D, Sherman SI. Antitumor activity of cabozantinib (XL184) in a cohort of patients (pts) with differentiated thyroid cancer (DTC). Amer Soc Clin Oncol (ASCO), 2012. e-Pub 2012.
Schlumberger M, Jarzab B, Cabanillas ME, Robinson B, Pacini F, Ball DW, McCaffrey JC, Newbold K, Allison R, Martins R, Licitra LF, Shah MH, Bodenner D, Elisei R, Burmeister LA, Funahashi Y, Sellecchia R, Andresen C, O'Brien JP, Sherman SI. A phase II trial of the multitargeted kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer (MTC). Amer Soc Clin Oncol (ASCO), 2012. e-Pub 2012.
Schoffski P, Elisei R, Muller S, Brose MS, Shah MH, Licitra LF, Jarzab B, Medvedev V, Kreissl M, Niederle B, Cohen EEW, Wirth LJ, Ali HY, Hessel C, Yaron Y, Ball DW, Nelkin B, Sherman SI, Schlumberger M. An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline. Amer Soc Clin Oncol (ASCO), 2012. e-Pub 2012.
Ball DW, Sherman SI, Jarzab B, Cabanillas ME, Martins R, Shah MH, Bodenner D, Newbold K, Licitra LF, Topliss D, Allison R, Kadowaki T, Funahashi Y, Matijevic M, Sachdev P, O'Brien JP, Schlumberger M. Lenvatinib treatment of advanced RAI-refractory differentiated thyroid cancer (DTC): Cytokine and angiogenic factor (CAF) profiling in combination with tumor genetic analysis to identify markers associated with response. Amer Soc Clin Oncol (ASCO), 2012. e-Pub 2012.
Sherman SI, Jarzab B, Cabanillas ME, Licitra LF, Pacini F, Martins R, Robinson B, Ball D, McCaffrey J, Shah MH, Bodenner D, Allison R, Newbold K, Elisei R, O’Brien JP, Schlumberger M. A phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC). J Clin Oncol 29(15S):360s, 2011. e-Pub 2011.
Sherman SI, Michaelis CL, Gornet T, Fritsche HA, Waguespack SG, Hu MI, Busaidy NL, Jimenez C, Cabanillas ME, Cote GJ. EpCAM-bearing circulating tumor cells are detectable in patients with metastatic medullary but not differentiated thyroid carcinoma, 2010. e-Pub 2010.
Michaelis CL, Cote GJ, Santarpia L, Klein MJ, Gornet TG, Fritsche HA, Busaidy NL, Waguespack SG, Cabanillas ME, Hu MI, Jimenez C, Sherman SI. Detection of circulating tumor cells (CTCs) in patients with thyroid cancer. Endocr Rev 31(S1):S615, 2010. e-Pub 2010.
Kurzrock R, Cohen EE, Sherman SI, Pfister DG, Cohen RB, Ball D, Hong DS, Ng CS, Salgia R, Ratain MJ. Long-term results in a cohort of medullary thyroid cancer (MTC) patients (pts) in a phase I study of XL184 (BMS 907351), an oral inhibitor of MET, VEGFR2, and RET. Amer Soc Clin Oncol (ASCO), 2010. e-Pub 2010.
Bass MB, Davis MT, Kivman L, Khoo H, Notari K, Blumenschein Jr GR, Mackey JR, Sherman SI, Hei Y, Patterson SD. Placental growth factor as a marker of therapeutic response to treatment with motesanib in patients with progressive advanced thyroid cancer, advanced nonsquamous non-small cell lung cancer, and locally recurrent or advanced metastatic breast cancer. Amer Soc Clin Oncol (ASCO), 2010. e-Pub 2010.
Cabanillas ME, Kurzrock R, Sherman SI, Tsimberidou AM, Waguespack S, Naing A, Busaidy N, Gagel R, Wright JJ, Hong DS. Phase I trial of combination sorafenib and tipifarnib: The experience in advanced differentiated thyroid cancer (DTC) and medullary thyroid cancer (MTC). Amer Soc Clin Oncol (ASCO), 2010. e-Pub 2010.
Shah P, Busaidy NL, Kapoor S, Sherman SI, Lavis VR. Steroid Hyperglycemia is not benign. Amer Diabetes Assoc, 2009. e-Pub 2009.
Cabanillas ME, Waguespack SG, Bronstein Y, Williams M, Feng L, Sherman SI, Busaidy NL. Treatment (tx) with tyrosine kinase inhibitors (TKIs) for patients (pts) with differentiated thyroid cancer (DTC): The M. D. Anderson Cancer Center (MDACC) experience. Amer Soc Clin Oncol (ASCO), 2009. e-Pub 2009.
Kurzrock R, Sherman SI, Hong D, Ng C, Frye J, Janisch L, Ratain MJ, Salgia R. A phase 1 study of XL 184, a MET, VEGFR2, and RET kinase inhibitor, administered orally to patients with advanced malignancies, including a subgroup of patients with medullary thyroid cancer (MTC), 2008. e-Pub 2008.
Shah P, Cui J, Busaidy NL, Sherman SI, Lavis VR. Why is "New" Hyperglycemia Dangerous in the Cancer Hospital?. Diabetes 57:A297-A298, 2008. e-Pub 2008.
Salgia R, Hong D, Sherman SI, Ng C, Frye J, Janisch L, Ratain M, Kurzrock R. A phase 1 dose-escalation study of the safety and pharmacokinetics (PK) of XL184, a VEGFR and MET kinase inhibitor, administered orally to patients (Pts) with advanced malignancies. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, 2007. e-Pub 2007.
Schlumberger MJ, Sherman SI, Hoff AO, Baudin E, Chung KC, Foreman AJ, Mathias SD, Miller DP, Stepan DE. Diarrhea burden in medullary thyroid cancer (MTC) patients: Impact of motesanib diphosphate (AMG 706) on diarrhea symptoms, interim results. Endocrine Soc, 2007. e-Pub 2007.
Schlumberger MJ, Elisei R, Sherman SI, Bastholt L, Wirth L, Martins R, Licitra L, Jarzab B, Pacini F, Daumerie C, Droz JP, Shi Y, Y-N S, Stepan D. Initial results from a phase 2 trial of motesanib diphosphate (AMG 706) in patients (pts) with medullary thyroid cancer (MTC). Endocrine Soc, 2007. e-Pub 2007.
Sherman SI, Schlumberger MJ, Elisei R, Wirth L, Bastholt L, Droz JP, Martins RG, Hofmann M, Locati L, Pacini F, Eschenberg MJ, Stepan DE. Exacerbation of postsurgical hypothyroidism during treatment of thyroid carcinoma with motesanib diphosphate. Endocrine Soc, 2007. e-Pub 2007.
Sherman SI, Schlumberger MJ, Droz J, Hofmann M, Wirth L, Bastholt L, Martins RG, Licitra L, Shi Y, Stepan DE. Initial results from a phase 2 trial of motesanib diphosphate (AMG 706) in patients with differentiated thyroid cancer (DTC). Amer Soc Clin Oncol, 2007. e-Pub 2007.
Shaw SA, Yazbeck CF, Sherman SI, Mahajan A. Intracranial metastases and thyroid carcinoma: a 14 year experience at a single institution [Abbott Research Award Oral Presentation]. Endocrine Soc, 2007. e-Pub 2007.
Santarpia L, El-Naggar AK, Cote G, Myers JN, Litofsky D, Sherman SI. Role of Ras/Raf-MAPK/PI3K cascade in anaplastic thyroid transformation. [Oral Presentation]. Endocrine Soc, 2007. e-Pub 2007.
Mittendorf EA, Perrier ND, Shapiro S, Lee JE, Sherman SI, Evans DB. Annual RAI imaging after treatment for papillary thyroid cancer: Is it necessary?. Endocrine Soc, 2006. e-Pub 2006.
Brierley J, Glisson BS, Kane MA, Haugen BR, Litofsky DR, Study Group SSFTNTCTC. Bortezomib in patients with metastatic differentiated thyroid cancer: preliminary results of a multicenter phase II study. [Plenary Oral Presentation]. Amer Thyroid Assoc, 2006. e-Pub 2006.
Mazzaglia, P, Bigos T, Litofsky D, Ain KB, Brierley J, Cooper DS, Haugen B, Jonklaas J, Ladenson P, Ross D, Skarulis M, Sherman SI. Complications of surgery for thyroid carcinoma: a report from the National Thyroid Cancer Treatment Cooperative Study Group. [Oral Presentation]. Amer Assoc Endocrine Surg, 2004. e-Pub 2004.
Royal RE, Shapiro SE, Fritsche HA, Delpassand ES, Vassilopoulou-Sellin R, Sherman SI, Gagel RF, Evans DB, Lee JE. Improving the yield of preoperative parathyroid localization: Sestamibi imaging following thyroid suppression. Amer Assoc Endocrine Surg, 2002. e-Pub 2002.
Pederson LC, Shapiro SE, Fritsche HA, Delpassand ES, Vassilopoulou-Sellin R, Sherman SI, Gagel RF, Evans DB, Lee JE. Maximizing parathyroid preservation in central neck surgery: Potential role for intraoperative gamma probe identification of normal parathyroid glands. Amer Assoc Endocrine Surg, 2002. e-Pub 2002.
Sherman SI, Lopez-Penabad L, Garden A, Burgess MA, Guthrie L, Gourgiotis L, Altemus R, Piekarz R, Sarlis NJ. Preliminary report on the use of paclitaxel as a sensitizer to the effects of external beam radiotherapy (EBRT) for control of locoregional disease in thyroid carcinoma [Oral Presentation]. Endocrine Soc, 2002. e-Pub 2002.
Kouvaraki M, Lee JE, Shapiro SE, Vassilopoulou-Sellin R, Sherman SI, Wirfel KL, Gagel RF, Evans DB. Pancreatic surgery in MEN1: Early results with a standard oncologic approach. Amer Assoc Endocrine Surg, 2002. e-Pub 2002.
Ghori, FY, Litofsky D, Jamal A, Yeung SJ, Arem R, Sherman SI. Influence of socioeconomic factors on presentation, management, and outcome of patients with differentiated thyroid carcinoma. Endocrine Soc, 2001. e-Pub 2001.
Jonklaas J, Sarlis N, Litofsky D, Cooper D, Ain K, Bigos S, Brierley J, Haugen B, Kim P, Ladenson P, Marks P, Robbins J, Ross D, Skarulis M, Maxon H, Sherman SI. Near-total/total thyroidectomy and thyroid hormone suppression therapy improve survival of patients with papillary thyroid carcinoma [Oral Short Call Presentation]. Amer Thyroid Assoc, 2001. e-Pub 2001.
Lopez-Penabad L, Ghori FY, Sherman SI. Diagnostic utility of recombinant human TSH testing during long-term follow-up of patients with differentiated thyroid carcinoma. Amer Assoc Clin Endocrinol, 2001. e-Pub 2001.
D’Amico, S, Lopez-Penabad L, Roman F, Sherman SI. ACTH-dependent Cushing’s syndrome in patients with prostate carcinoma. Amer Assoc Clin Endocrinol, 2001. e-Pub 2001.
Ghori, FY, Duvic M, Gagel RF, Hoff AO, Sherman SI. Thyroiditis following Ontak (DAB389-Il-2) therapy in patients with cutaneous T-cell lymphoma. Endocrine Soc, 2000. e-Pub 2000.
Sherman, SI, Ladenson PW, Haugen BR, Gutterman D, Smith MJ, Doerschuk AP, Davies T. Clinical utility of serum thyroglobulin measurements during follow-up of patients with differentiated thyroid carcinoma. Endocrine Soc, 2000. e-Pub 2000.
Sherman SI, Ghori FY, Duvic M. Increased levothyroxine dose requirements in CTCL patients treated with bexarotene (Targretin). 12th International Thyroid Congress, 2000. e-Pub 2000.
Maldonado, M, Sherman SI. Predictive value of clinicopathologic staging for medullary thyroid cancer. Amer Thyroid Assoc, 1999. e-Pub 1999.

Book Chapters

Sherman SI. RAI-Refractory Differentiated Thyroid Cancer with Multiple Organ Progressive Disease; RAI-Refractory Differentiated Thyroid Cancer and Lung Lesions Causing Bleeding; Differentiated Thyroid Cancer and Brain Metastases; RAI-Refractory, Advanced Differentiated Thyroid Cancer Receiving Tyrosine Kinase Inhibitor Treatment: Checking for Drug:Drug Interactions. In: Thyroid Cancer: A Case Based Approach. 2nd. Springer, 261-68; 269-274; 297-302; 303-310, 2021.
Filetti, S, Tuttle, RM, Sherman, SI. Medical management of differentiated epithelial cell thyroid cancer. In: Werner & Ingbar's The Thyroid. 11. Wolters Kluwer Health, 751-775, 2020.
Filetti S, Sherman SI. New (Medical) Treatment for Thyroid Carcinoma. In: Thyroid Diseases: Pathogenesis, Diagnosis, and Treatment. Springer, 645-670, 2018.
Sherman SI, Cabanillas ME, Lai SY. Neoplasms of the Thyroid. In: Holland - Frei Cancer Medicine. 9th. Wiley, 959-966, 2017.
Sherman SI. RAI-Refractory Differentiated Thyroid Cancer with Multiple Organ Progressive Disease; RAI-Refractory Differentiated Thyroid Cancer and Lung Lesions Causing Bleeding; Differentiated Thyroid Cancer and Brain Metastases; RAI-Refractory, Advanced Differentiated Thyroid Cancer Receiving Tyrosine Kinase Inhibitor Treatment: Checking for Drug:Drug Interactions. In: Thyroid Cancer. Springer, 279-86; 287-92; 307-14; 315-20, 2016.
Sherman SI. Thyroid Cancer. In: The Molecular Basis of Cancer: 4th Edition. 4th. Elsevier Press, 601-608, 2014.
Filetti S, Tuttle RM, Sherman SI. Medical Management of Differentiated Epithelial Thyroid Cancer. In: Werner & Ingbar's The Thyroid. 10th. Lippincott Williams & Wilkins, 725-743, 2013.
Sherman, SI, Perrier N, Clayman CL. 60 Years of Survival Outcomes at the University of Texas MD Anderson Cancer Center. In: Thyroid Cancer. Springer New York, 295-310, 2013.
Sherman SI. Biologically Targeted Therapies for Thyroid Cancers. In: Thyroid Cancer From Emergent Biotechnologies to Clinical Practice Guidelines. CRC Press Taylor & Francis Group, 329-349, 2011.
Sherman SI. Neoplasms of the Thyroid. In: Cancer Medicine. 8th Edition. People's Medical Publishing House-USA, 923-932, 2010.
Hu M, Sherman SI. Endocrine Complications of Head and Neck Surgery. In: Complications in Head and Neck Surgery. 2nd Edition. Mosby, 85-103, 2009.
Sherman SI. The Laboratory Approach to Thyroid Disorders. In: Medical Management of Thyroid Disease. 2nd Edition. Informa Healthcare USA, 1-38, 2008.
Sherman SI, Talbert RL. Thyroid Disorders. In: Pharmacotherapy: A Pathophysiologic Approach. 7th Edition. McGraw Hill, 1243-1264, 2008.
Sherman SI. Anaplastic Carcinoma: Clinical Aspects; Anaplastic Carcinoma: Prognosis; Thyroid Lymphoma. In: Thyroid Cancer: A Comprehensive Guide to Clinical Management. 2nd Edition. Humana Press, 615-20, 629-32, 647-52, 2006.
Sherman SI, Gillenwater AM. Neoplasia of the Thyroid. In: Cancer Medicine. 7th Edition. B.C. Decker, 1093-1102, 2006.
Sherman SI. Directions for Future Studies and Clinical Trials. In: Practical Management of Thyroid Cancer: A Multidisciplinary Approach. Springer, 429-34, 2005.
Sherman SI, Gagel RF. Disorders Affecting Multiple Endocrine Systems. In: Harrison’s Principles of Internal Medicine 16th edition. McGraw-Hill, 2231-2238, 2004.
Sherman SI, Lopez-Penabad L. The Use of Recombinant Human Thyrotropin in the Management of Thyroid Carcinoma and other Thyroid Disorders. In: Endocrine Replacement Therapy in Clinical Practice, 113-128, 2003.
Gillenwater AM, Sherman SI, El-Naggar AK, Helmuth G. Hurthle Cell Carcinoma of the Thyroid. In: Surgery of the Thyroid and Parathyroid Glands. W.B. Saunders, 227-231, 2003.
Sherman SI, Gillenwater AM. Neoplasia of the Thyroid. In: Cancer Medicine 6th edition. Decker, 2003.
Hoff AO, Sherman SI, Gagel RF. Radioiodine Treatment in Differentiated Thyroid Malignancy. In: Endocrine Surgery of the Head and Neck. Delmar Learning, 201-208, 2002.
Sherman SI. The Laboratory Approach to Thyroid Disorders. In: Medical Management of Thyroid Disease. Marcel Decker, 2001.
Deftos L, Sherman SI, Gagel RF. Multiglandular Endocrine Disorders. In: Endocrinology and Metabolism. 4th edition. McGraw-Hill, 1355-1382, 2001.
Sherman SI, Gagel RF. Disorders Affecting Multiple Endocrine Systems. In: Harrison’s Principles of Internal Medicine 15th edition. McGraw-Hill, 2184-2192, 2001.
Sherman SI, Gillenwater AM. Neoplasia of the Thyroid. In: Cancer Medicine 5th edition. Decker, 2000.
Sherman SI. Anaplastic Carcinoma: Clinical Aspects; Anaplastic Carcinoma: Prognosis; Thyroid Lymphoma. In: Thyroid Cancer, Clinical Management. Humana Press, 319-326, 345-350, 351-358, 1999.
Sherman SI, Gagel RF. Disorders Affecting Multiple Endocrine Systems. In: Harrison’s Principles of Internal Medicine 14th edition. McGraw-Hill, 1997.
Chiu, AC, Sherman SI. Clinical Manifestations and Differential Diagnosis of Hypothyroidism. In: Thyroid Disease: Endocrinology, Surgery, Nuclear Medicine and Radiotherapy. 2nd edition. Lippincott-Raven, 379-392, 1997.
Sherman, SI, Ladenson PW. Thyroid Gland. In: Laboratory Medicine: The Selection and Interpretation of Clinical Laboratory Studies. Williams & Wilkins, 629-645, 1994.
Sherman, SI, Ladenson PW. Endocrine Complications of Head and Neck Surgery. In: Complications in Head and Neck Surgery. Mosby-Year Book, Inc, 83-93, 1993.

Letters to the Editor

Yin N, Sherman SI, Pak Y, Litofsky DR, Gianoukakis AG. Response to Rosário and Souza Côrtes re: "The De Novo Detection of Anti-Thyroglobulin Antibodies and Differentiated Thyroid Cancer Recurrence". Thyroid 30: 1689-1687, 2020.
Jonklaas J, Cooper DS, Ain KB, Bigos T, Brierley JD, Haugen BR, Ladenson PW, Magner J, Ross DS, Skarulis MC, Steward DL, Maxon HR, Sherman SI, Group (NTCTCSG) FTNTCTCS, Houston, Texas. Radioiodine therapy in patients with stage I differentiated thyroid cancer. Thyroid 20: 1423-4, 2010.
Ginsberg LE, Clayman GI, Edeiken-Monroe BS, Rohren E, Sherman SI. Not so fast on the thyroidectomy - response to Eloy, et al. AJNR Am J Neuroradiol 31: E30, 2010.
Sherman SI, Ladenson PW. Subacute thyroiditis causing thyroid storm. Thyroid 17: 283, 2007.
Lee JE, Evans DB, Sherman SI, Gagel RF. Evaluation of the incidental adrenal mass. Am J Med 103: 249-50, 1997.

Less

CV information above last modified March 06, 2026

Steven I. Sherman, M.D.

Present Title & Affiliation

Primary Appointment

Research Interests

Clinical Interests

Education & Training

Degree-Granting Education

Postgraduate Training

Licenses & Certifications

Experience & Service

Faculty Academic Appointments

Administrative Appointments/Responsibilities

Other Professional Positions

Extramural Institutional Committee Activities

Editorial Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Invited Articles

Review Articles

Professional Educational Materials

Other Articles

Editorials

Abstracts

Book Chapters

Letters to the Editor

Patient Reviews

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Help #EndCancer

Steven I. Sherman, M.D.

Present Title & Affiliation

Primary Appointment

Research Interests

Clinical Interests

Education & Training

Degree-Granting Education

Postgraduate Training

Licenses & Certifications

Experience & Service

Faculty Academic Appointments

Administrative Appointments/Responsibilities

Other Professional Positions

Extramural Institutional Committee Activities

Editorial Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Invited Articles

Review Articles

Professional Educational Materials

Other Articles

Editorials

Abstracts

Book Chapters

Letters to the Editor

Patient Reviews

Request an Appointment

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Shop UT MD Anderson